<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:z="http://www.zotero.org/namespaces/export#"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:bib="http://purl.org/net/biblio#"
 xmlns:foaf="http://xmlns.com/foaf/0.1/"
 xmlns:link="http://purl.org/rss/1.0/modules/link/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
    <bib:Article rdf:about="https://doi.org/10.1093/biostatistics/kxw041">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1465-4644"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Stephens</foaf:surname>
                        <foaf:givenName>Matthew</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9"/>
        <link:link rdf:resource="#item_10"/>
        <dc:title>False discovery rates: a new deal</dc:title>
        <dcterms:abstract>We introduce a new Empirical Bayes approach for large-scale hypothesis testing, including estimating false discovery rates (FDRs), and effect sizes. This approach has two key differences from existing approaches to FDR analysis. First, it assumes that the distribution of the actual (unobserved) effects is unimodal, with a mode at 0. This “unimodal assumption” (UA), although natural in many contexts, is not usually incorporated into standard FDR analysis, and we demonstrate how incorporating it brings many benefits. Specifically, the UA facilitates efficient and robust computation—estimating the unimodal distribution involves solving a simple convex optimization problem—and enables more accurate inferences provided that it holds. Second, the method takes as its input two numbers for each test (an effect size estimate and corresponding standard error), rather than the one number usually used ($p$ value or $z$ score). When available, using two numbers instead of one helps account for variation in measurement precision across tests. It also facilitates estimation of effects, and unlike standard FDR methods, our approach provides interval estimates (credible regions) for each effect in addition to measures of significance. To provide a bridge between interval estimates and significance measures, we introduce the term “local false sign rate” to refer to the probability of getting the sign of an effect wrong and argue that it is a superior measure of significance than the local FDR because it is both more generally applicable and can be more robustly estimated. Our methods are implemented in an R package ashr available from http://github.com/stephens999/ashr.</dcterms:abstract>
        <dc:date>April 1, 2017</dc:date>
        <z:shortTitle>False discovery rates</z:shortTitle>
        <z:libraryCatalog>Silverchair</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>https://doi.org/10.1093/biostatistics/kxw041</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-17 18:26:32</dcterms:dateSubmitted>
        <bib:pages>275-294</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1465-4644">
        <prism:volume>18</prism:volume>
        <dc:title>Biostatistics</dc:title>
        <dc:identifier>DOI 10.1093/biostatistics/kxw041</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Biostatistics</dcterms:alternative>
        <dc:identifier>ISSN 1465-4644</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_9">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://academic.oup.com/biostatistics/article-pdf/18/2/275/11057424/kxw041.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-17 18:26:37</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_10">
        <z:itemType>attachment</z:itemType>
        <dc:title>Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://academic.oup.com/biostatistics/article/18/2/275/2557030</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-17 18:27:02</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682734/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1179-5549"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gil-Gil</foaf:surname>
                        <foaf:givenName>Miguel J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mesia</foaf:surname>
                        <foaf:givenName>Carlos</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rey</foaf:surname>
                        <foaf:givenName>Montserrat</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bruna</foaf:surname>
                        <foaf:givenName>Jordi</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_14"/>
        <link:link rdf:resource="#item_13"/>
        <dc:title>Bevacizumab for the Treatment of Glioblastoma</dc:title>
        <dcterms:abstract>Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months. GBM is 1 of the most vascularized human tumors and GBM cells produce vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF, has demonstrated activity in vitro and in phase II trials in relapse, as well as in 1 phase III trial as first line therapy. Bevacizumab also improves quality of life for patients suffering GBM. This paper reviews the mechanism of action of bevacizumab, its metabolism and pharmacokinetic profile. It summarizes the clinical studies in recurrent and newly diagnosed GBM, its potential side effects and complications and its place in therapy.</dcterms:abstract>
        <dc:date>2013-6-06</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682734/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:11:50</dcterms:dateSubmitted>
        <dc:description>PMID: 23843722
PMCID: PMC3682734</dc:description>
        <bib:pages>123-135</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1179-5549">
        <prism:volume>7</prism:volume>
        <dc:title>Clinical Medicine Insights. Oncology</dc:title>
        <dc:identifier>DOI 10.4137/CMO.S8503</dc:identifier>
        <dcterms:alternative>Clin Med Insights Oncol</dcterms:alternative>
        <dc:identifier>ISSN 1179-5549</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_14">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682734/pdf/cmo-7-2013-123.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:12:00</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_13">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682734/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:11:57</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095028/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>5</prism:volume>
                <dc:title>Clinical Medicine Insights. Oncology</dc:title>
                <dc:identifier>DOI 10.4137/CMO.S7232</dc:identifier>
                <dcterms:alternative>Clin Med Insights Oncol</dcterms:alternative>
                <dc:identifier>ISSN 1179-5549</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chamberlain</foaf:surname>
                        <foaf:givenName>Marc C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_17"/>
        <link:link rdf:resource="#item_16"/>
        <dc:title>Bevacizumab for the Treatment of Recurrent Glioblastoma</dc:title>
        <dcterms:abstract>Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels of vascular endothelial growth factor (VEGF), the dominant mediator of angiogenesis. A compelling biologic rationale, a need for improved therapy, and positive results from studies of bevacizumab in other cancers led to the evaluation of bevacizumab in the treatment of recurrent GBM. Bevacizumab, a humanized monoclonal antibody that targets VEGF, has been shown to improve patient outcomes in combination with chemotherapy (most commonly irinotecan) in recurrent GBM, and on the basis of positive results in two prospective phase 2 studies, bevacizumab was granted accelerated approval by the US Food and Drug Administration (FDA) as a single agent in recurrent GBM. Bevacizumab therapy is associated with manageable, class-specific toxicity as severe treatment-related adverse events are observed in only a minority of patients. With the goal of addressing questions and controversies regarding the optimal use of bevacizumab, the objective of this review is to provide a summary of the clinical efficacy and safety data of bevacizumab in patients with recurrent GBM, the practical issues surrounding the administration of bevacizumab, and ongoing investigations of bevacizumab in managing GBM.</dcterms:abstract>
        <dc:date>2011-5-02</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095028/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:14:15</dcterms:dateSubmitted>
        <dc:description>PMID: 21603247
PMCID: PMC3095028</dc:description>
        <bib:pages>117-129</bib:pages>
    </bib:Article>
    <z:Attachment rdf:about="#item_17">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095028/pdf/cmo-2011-117.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:14:20</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_16">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095028/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:14:17</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228024/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1083-7159"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kazazi-Hyseni</foaf:surname>
                        <foaf:givenName>Filis</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Beijnen</foaf:surname>
                        <foaf:givenName>Jos H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schellens</foaf:surname>
                        <foaf:givenName>Jan H. M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_20"/>
        <link:link rdf:resource="#item_19"/>
        <dc:title>Bevacizumab</dc:title>
        <dcterms:abstract>The use of bevacizumab as a single agent and in combination therapy for different tumor types is reviewed., After completing this course, the reader will be able to:
Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to predict degrees of patient response., This article is available for continuing medical education credit at CME.TheOncologist.com.</dcterms:abstract>
        <dc:date>2010-8</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228024/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:17:00</dcterms:dateSubmitted>
        <dc:description>PMID: 20688807
PMCID: PMC3228024</dc:description>
        <bib:pages>819-825</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1083-7159">
        <prism:volume>15</prism:volume>
        <dc:title>The Oncologist</dc:title>
        <dc:identifier>DOI 10.1634/theoncologist.2009-0317</dc:identifier>
        <prism:number>8</prism:number>
        <dcterms:alternative>Oncologist</dcterms:alternative>
        <dc:identifier>ISSN 1083-7159</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_20">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228024/pdf/onc819.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:17:00</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_19">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228024/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:17:00</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_21">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1549-490X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cohen</foaf:surname>
                        <foaf:givenName>Martin H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>Yuan Li</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Keegan</foaf:surname>
                        <foaf:givenName>Patricia</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pazdur</foaf:surname>
                        <foaf:givenName>Richard</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_22"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Aged</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Angiogenesis Inhibitors</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Antibodies, Monoclonal</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Antibodies, Monoclonal, Humanized</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Bevacizumab</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Brain Neoplasms</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Drug Approval</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Female</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Glioblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Male</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Middle Aged</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Neoplasm Recurrence, Local</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Prognosis</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Survival Rate</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>United States</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>United States Food and Drug Administration</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Vascular Endothelial Growth Factor A</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Young Adult</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme</dc:title>
        <dcterms:abstract>On May 5, 2009, the U.S. Food and Drug Administration granted accelerated approval to bevacizumab injection (Avastin; Genentech, Inc., South San Francisco, CA) as a single agent for patients with glioblastoma multiforme (GBM) with progressive disease following prior therapy. The approval was based on durable objective responses (independent radiologic review with stable or decreasing corticosteroid use). Two trials evaluating bevacizumab, 10 mg/kg by i.v. infusion every 2 weeks, were submitted. One trial also randomized patients to bevacizumab plus irinotecan treatment. All patients had received prior surgery, radiotherapy, and temozolomide. Patients with active brain hemorrhage were excluded. One trial enrolled 78 independently confirmed GBM patients. Partial responses were observed in 25.9% (95% confidence interval [CI], 17.0%-36.1%) of the patients. The median response duration was 4.2 months (95% CI, 3.0-5.7 months). The second trial enrolled 56 GBM patients. Partial responses were observed in 19.6% (95% CI, 10.9%-31.3%) of the patients. The median response duration was 3.9 months (95% CI, 2.4-17.4 months). Safety data were provided for the first study. The most frequently reported bevacizumab adverse events of any grade were infection, fatigue, headache, hypertension, epistaxis, and diarrhea. Grade 3-5 bevacizumab-related adverse events included bleeding/hemorrhage, central nervous system (CNS) hemorrhage, hypertension, venous and arterial thromboembolic events, wound-healing complications, proteinuria, gastrointestinal perforation, and reversible posterior leukoencephalopathy. The attribution of certain adverse events (e.g., CNS hemorrhage, wound-healing complications, and thromboembolic events) to either bevacizumab, underlying disease, or both could not be determined because of the single-arm, noncomparative study design.</dcterms:abstract>
        <dc:date>2009-11</dc:date>
        <z:language>eng</z:language>
        <z:shortTitle>FDA drug approval summary</z:shortTitle>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 19897538</dc:description>
        <bib:pages>1131-1138</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1549-490X">
        <prism:volume>14</prism:volume>
        <dc:title>The Oncologist</dc:title>
        <dc:identifier>DOI 10.1634/theoncologist.2009-0121</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>Oncologist</dcterms:alternative>
        <dc:identifier>ISSN 1549-490X</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_22">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/19897538</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-08-31 12:19:25</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378489/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0028-4793"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Das</foaf:surname>
                        <foaf:givenName>Sunit</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Marsden</foaf:surname>
                        <foaf:givenName>Philip A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_25"/>
        <link:link rdf:resource="#item_24"/>
        <dc:title>Angiogenesis in Glioblastoma</dc:title>
        <dc:date>2013-10-17</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378489/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-01 15:49:16</dcterms:dateSubmitted>
        <dc:description>PMID: 24131182
PMCID: PMC5378489</dc:description>
        <bib:pages>1561-1563</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0028-4793">
        <prism:volume>369</prism:volume>
        <dc:title>The New England journal of medicine</dc:title>
        <dc:identifier>DOI 10.1056/NEJMcibr1309402</dc:identifier>
        <prism:number>16</prism:number>
        <dcterms:alternative>N Engl J Med</dcterms:alternative>
        <dc:identifier>ISSN 0028-4793</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_25">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378489/pdf/nihms-611606.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-01 15:49:18</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_24">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378489/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-01 15:49:16</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682776/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0025-7974"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Meng</foaf:surname>
                        <foaf:givenName>Xiangying</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Rugang</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>Ge</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dong</foaf:surname>
                        <foaf:givenName>Dapeng</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>Lijuan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Shikai</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_28"/>
        <link:link rdf:resource="#item_27"/>
        <dc:title>Efficacy and safety of bevacizumab treatment for refractory brain edema</dc:title>
        <dcterms:abstract>Objective:
This retrospective study investigated the efficacy and safety of bevacizumab treatment for refractory brain edema.

Methods:
Between March 2009 and December 2015, bevacizumab was used to treat 59 cases of brain metastatic patients with refractory brain edema. The median dose of bevacizumab was 4.68 mg/kg (range 2.8–6.52 mg/kg). The clinical-pathological data, the efficacy, and the side effects of bevacizumab were recorded. Magnetic resonance imaging (MRI) was performed before and after bevacizumab treatment. Tumor and edema volumes were measured separately.

Results:
The clinical symptoms of 50 out of 59 cases (84.74%) improved the day after the bevacizumab treatment, and the edema volumes of 55 (93.22%) cases were reduced after the bevacizumab treatment. The average edema volume was significantly reduced after bevacizumab treatment from 125,583.43 ± 14,093.27 to 71,613.42 ± 9473.42 mm3 (Mann–Whitney rank test, P &lt; .01), and the average edema index was significantly reduced from 25.66 ± 11.54 to 17.87 ± 6.87 (Mann–Whitney rank test, P &lt; .01). One patient died from a hemorrhage due to a cancerous-ulcer of the maxillary sinus. The main complication observed was hypertension, which was observed in 11 cases (18.6%).

Conclusion:
The effective rate of bevacizumab for refractory brain edema is 84.74%. Hypertension was the main side effect of the bevacizumab treatment. Bevacizumab is an effective and relatively safe treatment for brain edema.</dcterms:abstract>
        <dc:date>2017-11-03</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682776/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-01 17:20:12</dcterms:dateSubmitted>
        <dc:description>PMID: 29095257
PMCID: PMC5682776</dc:description>
        <bib:pages>e8280</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0025-7974">
        <prism:volume>96</prism:volume>
        <dc:title>Medicine</dc:title>
        <dc:identifier>DOI 10.1097/MD.0000000000008280</dc:identifier>
        <prism:number>44</prism:number>
        <dcterms:alternative>Medicine (Baltimore)</dcterms:alternative>
        <dc:identifier>ISSN 0025-7974</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_28">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682776/pdf/medi-96-e8280.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-01 17:20:15</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_27">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682776/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-01 17:20:13</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_29">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1573-7209"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brown</foaf:surname>
                        <foaf:givenName>Kathleen C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lau</foaf:surname>
                        <foaf:givenName>Jamie K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dom</foaf:surname>
                        <foaf:givenName>Aaron M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Witte</foaf:surname>
                        <foaf:givenName>Theodore R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>Haitao</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Crabtree</foaf:surname>
                        <foaf:givenName>Clayton M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shah</foaf:surname>
                        <foaf:givenName>Yashoni H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shiflett</foaf:surname>
                        <foaf:givenName>Brandon S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Marcelo</foaf:surname>
                        <foaf:givenName>Aileen J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Proper</foaf:surname>
                        <foaf:givenName>Nancy A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hardman</foaf:surname>
                        <foaf:givenName>W. Elaine</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Egleton</foaf:surname>
                        <foaf:givenName>Richard D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Yi Charlie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mangiarua</foaf:surname>
                        <foaf:givenName>Elsa I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dasgupta</foaf:surname>
                        <foaf:givenName>Piyali</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_30"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>alpha7 Nicotinic Acetylcholine Receptor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Animals</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cell Proliferation</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Chickens</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Down-Regulation</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Early Growth Response Protein 1</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Endothelial Cells</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Fibroblast Growth Factor 2</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Lung</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Mice</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Mice, Nude</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Microvessels</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Models, Biological</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Neovascularization, Physiologic</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Nicotine</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Nicotinic Antagonists</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Quaternary Ammonium Compounds</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Rats</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Receptors, Nicotinic</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Signal Transduction</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Stilbenes</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway</dc:title>
        <dcterms:abstract>Small cell lung cancer (SCLC) demonstrates a strong etiological association with smoking. Although cigarette smoke is a mixture of about 4,000 compounds, nicotine is the addictive component of cigarette smoke. Several convergent studies have shown that nicotine promotes angiogenesis in lung cancers via the α7-nicotinic acetylcholine receptor (α7-nAChR) on endothelial cells. Therefore, we conjectured that α7-nAChR antagonists may attenuate nicotine-induced angiogenesis and be useful for the treatment of human SCLC. For the first time, our study explores the anti-angiogenic activity of MG624, a small-molecule α7-nAChR antagonist, in several experimental models of angiogenesis. We observed that MG624 potently suppressed the proliferation of primary human microvascular endothelial cells of the lung (HMEC-Ls). Furthermore, MG624 displayed robust anti-angiogenic activity in the Matrigel, rat aortic ring and rat retinal explant assays. The anti-angiogenic activity of MG624 was assessed by two in vivo models, namely the chicken chorioallantoic membrane model and the nude mice model. In both of these experimental models, MG624 inhibited angiogenesis of human SCLC tumors. Most importantly, the administration of MG624 was not associated with any toxic side effects, lethargy or discomfort in the mice. The anti-angiogenic activity of MG624 was mediated via the suppression of nicotine-induced FGF2 levels in HMEC-Ls. MG624 decreased nicotine-induced early growth response gene 1 (Egr-1) levels in HMEC-Ls, and reduced the levels of Egr-1 on the FGF2 promoter. Consequently, this process decreased FGF2 levels and angiogenesis. Our findings suggest that the anti-angiogenic effects of MG624 could be useful in anti-angiogenic therapy of human SCLCs.</dcterms:abstract>
        <dc:date>2012-03</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 22198237</dc:description>
        <bib:pages>99-114</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1573-7209">
        <prism:volume>15</prism:volume>
        <dc:title>Angiogenesis</dc:title>
        <dc:identifier>DOI 10.1007/s10456-011-9246-9</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Angiogenesis</dcterms:alternative>
        <dc:identifier>ISSN 1573-7209</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_30">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/22198237</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-01 20:57:12</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.hindawi.com/journals/jo/2011/456743/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1687-8450"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Singh</foaf:surname>
                        <foaf:givenName>Sandeep</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pillai</foaf:surname>
                        <foaf:givenName>Smitha</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chellappan</foaf:surname>
                        <foaf:givenName>Srikumar</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_32"/>
        <link:link rdf:resource="#item_33"/>
        <dc:title>Nicotinic Acetylcholine Receptor Signaling in Tumor Growth and Metastasis</dc:title>
        <dcterms:abstract>Cigarette smoking is highly correlated with the onset of a variety of human cancers, and continued smoking is known to abrogate the beneficial effects of cancer therapy. While tobacco smoke contains hundreds of molecules that are known carcinogens, nicotine, the main addictive component of tobacco smoke, is not carcinogenic. At the same time, nicotine has been shown to promote cell proliferation, angiogenesis, and epithelial-mesenchymal transition, leading to enhanced tumor growth and metastasis. These effects of nicotine are mediated through the nicotinic acetylcholine receptors that are expressed on a variety of neuronal and nonneuronal cells. Specific signal transduction cascades that emanate from different nAChR subunits or subunit combinations facilitate the proliferative and prosurvival functions of nicotine. Nicotinic acetylcholine receptors appear to stimulate many downstream signaling cascades induced by growth factors and mitogens. It has been suggested that antagonists of nAChR signaling might have antitumor effects and might open new avenues for combating tobacco-related cancer. This paper examines the historical data connecting nicotine tumor progression and the recent efforts to target the nicotinic acetylcholine receptors to combat cancer.</dcterms:abstract>
        <dc:date>2011/03/30</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>www.hindawi.com</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.hindawi.com/journals/jo/2011/456743/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-02 19:11:01</dcterms:dateSubmitted>
        <dc:description>Publisher: Hindawi</dc:description>
        <bib:pages>e456743</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1687-8450">
        <prism:volume>2011</prism:volume>
        <dc:title>Journal of Oncology</dc:title>
        <dc:identifier>DOI 10.1155/2011/456743</dc:identifier>
        <dc:identifier>ISSN 1687-8450</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_32">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://downloads.hindawi.com/journals/jo/2011/456743.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-02 19:11:05</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_33">
        <z:itemType>attachment</z:itemType>
        <dc:title>Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.hindawi.com/journals/jo/2011/456743/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-02 19:11:17</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://doi.org/10.1186/s13058-015-0610-3">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1465-542X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Siraj</foaf:surname>
                        <foaf:givenName>Abdul K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Beg</foaf:surname>
                        <foaf:givenName>Shaham</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jehan</foaf:surname>
                        <foaf:givenName>Zeenath</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Prabhakaran</foaf:surname>
                        <foaf:givenName>Sarita</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ahmed</foaf:surname>
                        <foaf:givenName>Maqbool</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>R.Hussain</foaf:surname>
                        <foaf:givenName>Azhar</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Al-Dayel</foaf:surname>
                        <foaf:givenName>Fouad</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tulbah</foaf:surname>
                        <foaf:givenName>Asma</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ajarim</foaf:surname>
                        <foaf:givenName>Dahish</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Al-Kuraya</foaf:surname>
                        <foaf:givenName>Khawla S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_35"/>
        <link:link rdf:resource="#item_36"/>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Anaplastic Large Cell Lymphoma</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Anaplastic Lymphoma Kinase</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Anaplastic Lymphoma Kinase Gene</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Anaplastic Lymphoma Kinase Inhibitor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Inflammatory Breast Cancer</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>ALK alteration is a frequent event in aggressive breast cancers</dc:title>
        <dcterms:abstract>Breast cancer is the most common female malignancy worldwide and, despite improvements in treatment modalities, there are increased chances of recurrence and metastasis in a substantial number of cases and it remains one of the major causes of mortality among female cancer patients. Anaplastic lymphoma kinase (ALK) gene has been found to be altered in several solid and hematologic tumors. We aimed to comprehensively study the prevalence of ALK expression, and changes in copy number and translocation in a large cohort of breast cancer cases in a Middle Eastern population.</dcterms:abstract>
        <dc:date>September 17, 2015</dc:date>
        <z:libraryCatalog>BioMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>https://doi.org/10.1186/s13058-015-0610-3</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-02 19:17:11</dcterms:dateSubmitted>
        <bib:pages>127</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1465-542X">
        <prism:volume>17</prism:volume>
        <dc:title>Breast Cancer Research</dc:title>
        <dc:identifier>DOI 10.1186/s13058-015-0610-3</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Breast Cancer Research</dcterms:alternative>
        <dc:identifier>ISSN 1465-542X</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_35">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://breast-cancer-research.biomedcentral.com/track/pdf/10.1186/s13058-015-0610-3</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-02 19:17:15</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_36">
        <z:itemType>attachment</z:itemType>
        <dc:title>Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0610-3</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-02 19:17:25</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.sciencedirect.com/science/article/pii/S0165027005004073">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0165-0270"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shastry Akella</foaf:surname>
                        <foaf:givenName>N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>Qiang</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Menegazzo</foaf:surname>
                        <foaf:givenName>Ingrid</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Wenquan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yancey Gillespie</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Robert Grammer</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gladson</foaf:surname>
                        <foaf:givenName>Candece L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nabors</foaf:surname>
                        <foaf:givenName>L. Burton</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_59"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Glioblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Animal models</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Glioma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Invasion</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Mathematical models</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Serial microscopy</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>A novel technique to quantify glioma tumor invasion using serial microscopy sections</dc:title>
        <dcterms:abstract>Here we present a new technique to quantitatively characterize malignant glioma invasion in a syngeneic mouse model. The GL261 mouse malignant glioma cell line was injected intracerebrally into the C57B1/6 black mouse and allowed to propagate for 10 or 17 days, followed by euthanasia of the animal, harvesting of the brain, fixation, and serial sectioning. Histologic examination was performed and the primary tumor mass and discontinuous sites of tumor invasion were traced on digital images of serial microscopy sections, followed by analysis of the invasion characteristics using a custom-written MATLAB program. We found a significant increase in the number of discontinuous tumor invasion sites and in the distance of these sites from the tumor centroid in mice that were euthanized at 17 days post-tumor cell injection, as compared to mice euthanized at 10 days. Furthermore, a scatter plot analyses indicated that the invasion site data could be grouped based on the characteristics of area and distance from the tumor centroid to reveal significant differences between the two experimental groups of mice. This quantitative method will allow a future in vivo analysis of invasion characteristics in glioma cells expressing altered levels or function of invasion genes, and of new therapy targeting invading glioma cells.</dcterms:abstract>
        <dc:date>June 15, 2006</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>ScienceDirect</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.sciencedirect.com/science/article/pii/S0165027005004073</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:05:45</dcterms:dateSubmitted>
        <bib:pages>183-189</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0165-0270">
        <prism:volume>153</prism:volume>
        <dc:title>Journal of Neuroscience Methods</dc:title>
        <dc:identifier>DOI 10.1016/j.jneumeth.2005.10.026</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Journal of Neuroscience Methods</dcterms:alternative>
        <dc:identifier>ISSN 0165-0270</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_59">
        <z:itemType>attachment</z:itemType>
        <dc:title>ScienceDirect Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.sciencedirect.com/science/article/pii/S0165027005004073</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:05:54</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0070804">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1932-6203"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Wei Michael</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>Ping</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kar</foaf:surname>
                        <foaf:givenName>Niladri</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Burgett</foaf:surname>
                        <foaf:givenName>Monica</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Muller-Greven</foaf:surname>
                        <foaf:givenName>Gaelle</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nowacki</foaf:surname>
                        <foaf:givenName>Amy S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Distelhorst</foaf:surname>
                        <foaf:givenName>Clark W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lathia</foaf:surname>
                        <foaf:givenName>Justin D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rich</foaf:surname>
                        <foaf:givenName>Jeremy N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kappes</foaf:surname>
                        <foaf:givenName>John C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gladson</foaf:surname>
                        <foaf:givenName>Candece L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_61"/>
        <link:link rdf:resource="#item_62"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Apoptosis</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Autophagic cell death</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Breast cancer</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cancers and neoplasms</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Euthanasia</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Mouse models</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Non-small cell lung cancer</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Prostate cancer</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>Lyn Facilitates Glioblastoma Cell Survival under Conditions of Nutrient Deprivation by Promoting Autophagy</dc:title>
        <dcterms:abstract>Members of the Src family kinases (SFK) can modulate diverse cellular processes, including division, death and survival, but their role in autophagy has been minimally explored. Here, we investigated the roles of Lyn, a SFK, in promoting the survival of human glioblastoma tumor (GBM) cells in vitro and in vivo using lentiviral vector-mediated expression of constitutively-active Lyn (CA-Lyn) or dominant-negative Lyn (DN-Lyn). Expression of either CA-Lyn or DN-Lyn had no effect on the survival of U87 GBM cells grown under nutrient-rich conditions. In contrast, under nutrient-deprived conditions (absence of supplementation with L-glutamine, which is essential for growth of GBM cells, and FBS) CA-Lyn expression enhanced survival and promoted autophagy as well as inhibiting cell death and promoting proliferation. Expression of DN-Lyn promoted cell death. In the nutrient-deprived GBM cells, CA-Lyn expression enhanced AMPK activity and reduced the levels of pS6 kinase whereas DN-Lyn enhanced the levels of pS6 kinase. Similar results were obtained in vitro using another cultured GBM cell line and primary glioma stem cells. On propagation of the transduced GBM cells in the brains of nude mice, the CA-Lyn xenografts formed larger tumors than control cells and autophagosomes were detectable in the tumor cells. The DN-Lyn xenografts formed smaller tumors and contained more apoptotic cells. Our findings suggest that on nutrient deprivation in vitro Lyn acts to enhance the survival of GBM cells by promoting autophagy and proliferation as well as inhibiting cell death, and Lyn promotes the same effects in vivo in xenograft tumors. As the levels of Lyn protein or its activity are elevated in several cancers these findings may be of broad relevance to cancer biology.</dcterms:abstract>
        <dc:date>Aug 2, 2013</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>PLoS Journals</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0070804</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:08:03</dcterms:dateSubmitted>
        <dc:description>Publisher: Public Library of Science</dc:description>
        <bib:pages>e70804</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1932-6203">
        <prism:volume>8</prism:volume>
        <dc:title>PLOS ONE</dc:title>
        <dc:identifier>DOI 10.1371/journal.pone.0070804</dc:identifier>
        <prism:number>8</prism:number>
        <dcterms:alternative>PLOS ONE</dcterms:alternative>
        <dc:identifier>ISSN 1932-6203</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_61">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0070804&amp;type=printable</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:08:05</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_62">
        <z:itemType>attachment</z:itemType>
        <dc:title>Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0070804</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:08:16</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://clincancerres.aacrjournals.org/content/23/22/7059">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1078-0432,%201557-3265"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Müller-Greven</foaf:surname>
                        <foaf:givenName>Gaëlle</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Carlin</foaf:surname>
                        <foaf:givenName>Cathleen R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Burgett</foaf:surname>
                        <foaf:givenName>Monica E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ahluwalia</foaf:surname>
                        <foaf:givenName>Manmeet S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lauko</foaf:surname>
                        <foaf:givenName>Adam</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nowacki</foaf:surname>
                        <foaf:givenName>Amy S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Herting</foaf:surname>
                        <foaf:givenName>Cameron J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qadan</foaf:surname>
                        <foaf:givenName>Maha A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bredel</foaf:surname>
                        <foaf:givenName>Markus</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Toms</foaf:surname>
                        <foaf:givenName>Steven A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lathia</foaf:surname>
                        <foaf:givenName>Justin D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hambardzumyan</foaf:surname>
                        <foaf:givenName>Dolores</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sarkaria</foaf:surname>
                        <foaf:givenName>Jann N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hamerlik</foaf:surname>
                        <foaf:givenName>Petra</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gladson</foaf:surname>
                        <foaf:givenName>Candece L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_70"/>
        <link:link rdf:resource="#item_72"/>
        <link:link rdf:resource="#item_71"/>
        <dc:title>Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival</dc:title>
        <dcterms:abstract>Purpose: Bevacizumab, a humanized monoclonal antibody to VEGF, is used routinely in the treatment of patients with recurrent glioblastoma (GBM). However, very little is known regarding the effects of bevacizumab on the cells in the perivascular space in tumors.
Experimental Design: Established orthotopic xenograft and syngeneic models of GBM were used to determine entry of monoclonal anti-VEGF-A into, and uptake by cells in, the perivascular space. Based on the results, we examined CD133+ cells derived from GBM tumors in vitro. Bevacizumab internalization, trafficking, and effects on cell survival were analyzed using multilabel confocal microscopy, immunoblotting, and cytotoxicity assays in the presence/absence of inhibitors.
Results: In the GBM mouse models, administered anti-mouse-VEGF-A entered the perivascular tumor niche and was internalized by Sox2+/CD44+ tumor cells. In the perivascular tumor cells, bevacizumab was detected in the recycling compartment or the lysosomes, and increased autophagy was found. Bevacizumab was internalized rapidly by CD133+/Sox2+-GBM cells in vitro through macropinocytosis with a fraction being trafficked to a recycling compartment, independent of FcRn, and a fraction to lysosomes. Bevacizumab treatment of CD133+ GBM cells depleted VEGF-A and induced autophagy thereby improving cell survival. An inhibitor of lysosomal acidification decreased bevacizumab-induced autophagy and increased cell death. Inhibition of macropinocytosis increased cell death, suggesting macropinocytosis of bevacizumab promotes CD133+ cell survival.
Conclusions: We demonstrate that bevacizumab is internalized by Sox2+/CD44+-GBM tumor cells residing in the perivascular tumor niche. Macropinocytosis of bevacizumab and trafficking to the lysosomes promotes CD133+ cell survival, as does the autophagy induced by bevacizumab depletion of VEGF-A. Clin Cancer Res; 23(22); 7059–71. ©2017 AACR.</dcterms:abstract>
        <dc:date>2017/11/15</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>clincancerres.aacrjournals.org</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://clincancerres.aacrjournals.org/content/23/22/7059</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:09:36</dcterms:dateSubmitted>
        <dc:rights>©2017 American Association for Cancer Research.</dc:rights>
        <dc:description>Publisher: American Association for Cancer Research
Section: Biology of Human Tumors
PMID: 28912141</dc:description>
        <bib:pages>7059-7071</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1078-0432,%201557-3265">
        <prism:volume>23</prism:volume>
        <dc:title>Clinical Cancer Research</dc:title>
        <dc:identifier>DOI 10.1158/1078-0432.CCR-17-0249</dc:identifier>
        <prism:number>22</prism:number>
        <dcterms:alternative>Clin Cancer Res</dcterms:alternative>
        <dc:identifier>ISSN 1078-0432, 1557-3265</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_70">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://clincancerres.aacrjournals.org/content/clincanres/23/22/7059.full.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:09:39</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_72">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/28912141</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:09:53</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_71">
        <z:itemType>attachment</z:itemType>
        <dc:title>Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://clincancerres.aacrjournals.org/content/23/22/7059?iss=22</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:09:51</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_73">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1940-6029"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Crane</foaf:surname>
                        <foaf:givenName>Ashley M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bhattacharya</foaf:surname>
                        <foaf:givenName>Sanjoy K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_74"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Animals</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cell Proliferation</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Cells, Cultured</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Adult Stem Cells</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Bromodeoxyuridine</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cell Culture Techniques</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>DNA</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>DNA Replication</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Fluorescent Antibody Technique, Indirect</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Limbus Corneae</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>The use of bromodeoxyuridine incorporation assays to assess corneal stem cell proliferation</dc:title>
        <dcterms:abstract>Bromodeoxyuridine (BrdU) incorporation assays have long been used to detect DNA synthesis in vivo and in vitro. The key principle of this method is that BrdU incorporated as a thymidine analog into nuclear DNA represents a label that can be tracked using antibody probes. In this chapter, we describe BrdU incorporation into limbal stem cells. The colorimetric reaction produced by this assay can be detected by immunohistochemistry, and using appropriate controls, it can be used for determination of proliferating properties of restricted progenitor cells derived from the cornea.</dcterms:abstract>
        <dc:date>2013</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 23690005</dc:description>
        <bib:pages>65-70</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1940-6029">
        <prism:volume>1014</prism:volume>
        <dc:title>Methods in Molecular Biology (Clifton, N.J.)</dc:title>
        <dc:identifier>DOI 10.1007/978-1-62703-432-6_4</dc:identifier>
        <dcterms:alternative>Methods Mol Biol</dcterms:alternative>
        <dc:identifier>ISSN 1940-6029</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_74">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/23690005</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:13:42</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_77">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>731</prism:volume>
                <dc:title>Methods in Molecular Biology (Clifton, N.J.)</dc:title>
                <dc:identifier>DOI 10.1007/978-1-61779-080-5_20</dc:identifier>
                <dcterms:alternative>Methods Mol Biol</dcterms:alternative>
                <dc:identifier>ISSN 1940-6029</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>van Meerloo</foaf:surname>
                        <foaf:givenName>Johan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kaspers</foaf:surname>
                        <foaf:givenName>Gertjan J. L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cloos</foaf:surname>
                        <foaf:givenName>Jacqueline</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_78"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cell Culture Techniques</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Cell Line</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Cytotoxins</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
                <rdf:value>Drug-Related Side Effects and Adverse Reactions</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Formazans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tetrazolium Salts</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Thiazoles</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Toxicity Tests</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>Cell sensitivity assays: the MTT assay</dc:title>
        <dcterms:abstract>The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay is based on the conversion of MTT into formazan crystals by living cells, which determines mitochondrial activity. Since for most cell populations the total mitochondrial activity is related to the number of viable cells, this assay is broadly used to measure the in vitro cytotoxic effects of drugs on cell lines or primary patient cells. In this chapter the protocol of the assay is described including important considerations relevant for each step of the assay as well as its limitations and possible applications.</dcterms:abstract>
        <dc:date>2011</dc:date>
        <z:language>eng</z:language>
        <z:shortTitle>Cell sensitivity assays</z:shortTitle>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 21516412</dc:description>
        <bib:pages>237-245</bib:pages>
    </bib:Article>
    <z:Attachment rdf:about="#item_78">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/21516412</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:15:41</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_79">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1064-3745"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Hong-Chen</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_80"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Animals</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Cell Movement</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Cell Line</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Chemotaxis, Leukocyte</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cytological Techniques</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Dogs</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>Boyden chamber assay</dc:title>
        <dcterms:abstract>The Boyden chamber assay, originally introduced by Boyden for the analysis of leukocyte chemotaxis, is based on a chamber of two medium-filled compartments separated by a microporous membrane. In general, cells are placed in the upper compartment and are allowed to migrate through the pores of the membrane into the lower compartment, in which chemotactic agents are present. After an appropriate incubation time, the membrane between the two compartments is fixed and stained, and the number of cells that have migrated to the lower side of the membrane is determined. Therefore, the Boyden chamber-based cell migration assay has also been called filter membrane migration assay, trans-well migration assay, or chemotaxis assay. A number of different Boyden chamber devices are available commercially. The method described in this chapter is intended specifically for measuring the migration of Madin-Darby canine kidney cells using a 48-well chamber from Neuro Probe, Inc.</dcterms:abstract>
        <dc:date>2005</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 15576901</dc:description>
        <bib:pages>15-22</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1064-3745">
        <prism:volume>294</prism:volume>
        <dc:title>Methods in Molecular Biology (Clifton, N.J.)</dc:title>
        <dc:identifier>DOI 10.1385/1-59259-860-9:015</dc:identifier>
        <dcterms:alternative>Methods Mol Biol</dcterms:alternative>
        <dc:identifier>ISSN 1064-3745</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_80">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/15576901</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:17:16</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355275/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1949-2553"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pepper</foaf:surname>
                        <foaf:givenName>Chris</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tu</foaf:surname>
                        <foaf:givenName>Henry</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Morrill</foaf:surname>
                        <foaf:givenName>Paul</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Garcia-Rates</foaf:surname>
                        <foaf:givenName>Sara</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fegan</foaf:surname>
                        <foaf:givenName>Chris</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Greenfield</foaf:surname>
                        <foaf:givenName>Susan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_83"/>
        <link:link rdf:resource="#item_82"/>
        <dc:title>Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor</dc:title>
        <dcterms:abstract>A 14mer peptide (T14) derived from the C-terminus of acetylcholinesterase (AChE) selectively activates metastatic breast cancer cells via the alpha-7 nicotinic receptor (α7 nAChR). This naturally occurring peptide is also present in brain, is elevated in Alzheimer's disease, and is antagonised by a cyclized variant (NBP-14). Here we investigated the effects of NBP-14 in six different cancer cell lines, primary leukemia B-cells and normal B-cells. All cells tested expressed α7 nAChR, intracellular and extracellular T14. However, NBP-14 showed low toxicity and weak anti-proliferative effects in the majority of the cell lines and was even less toxic in normal B-cells when compared to primary chronic lymphocytic leukemia cells (P &lt; 0.001). Given the potential role of T14 peptide in metastasis, we next investigated the effects of NBP-14 on tumor cell migration, where it caused a dose-dependent reduction. The extent of NBP-14 inhibition positively correlated with the migration of the cells (r2 = 0.45; P = 0.06). Furthermore, NBP-14 preferentially inhibited the migration of primary leukemia cells when compared with normal B-cells (P = 0.0002); when the normal B-cell data was excluded, this correlation was strengthened (r2 = 0.80; P = 0.006). Importantly, the constitutive α7 nAChR expression positively correlated with intracellular T14 levels (r2 = 0.91; P = 0.0003) and inversely correlated with extracellular T14 levels in the cell culture supernatants (r2 = −0.79; P = 0.034). However, in the presence of NBP-14, α7 nAChR expression was reduced (P = 0.04) and the most migratory cells showed the largest reduction in expression. In conclusion, NBP-14-mediated antagonism of the α7 nAChR offers a novel therapeutic strategy with the potential to inhibit tumor cell migration.</dcterms:abstract>
        <dc:date>2017-1-6</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355275/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:24:31</dcterms:dateSubmitted>
        <dc:description>PMID: 28077796
PMCID: PMC5355275</dc:description>
        <bib:pages>11414-11424</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1949-2553">
        <prism:volume>8</prism:volume>
        <dc:title>Oncotarget</dc:title>
        <dc:identifier>DOI 10.18632/oncotarget.14545</dc:identifier>
        <prism:number>7</prism:number>
        <dcterms:alternative>Oncotarget</dcterms:alternative>
        <dc:identifier>ISSN 1949-2553</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_83">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355275/pdf/oncotarget-08-11414.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:24:34</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_82">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355275/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:24:31</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_84">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1573-2568"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Shuhai</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kang</foaf:surname>
                        <foaf:givenName>Xiaoliang</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Guangwei</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Bingyuan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>Xiao</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Feng</foaf:surname>
                        <foaf:givenName>Yujie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_85"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>alpha7 Nicotinic Acetylcholine Receptor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Animals</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cell Proliferation</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Mice</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Mice, Nude</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Apoptosis</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Anticancer</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Bile Duct Neoplasms</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cell Line, Tumor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cholangiocarcinoma</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Disease Progression</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Epithelial-Mesenchymal Transition</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Epithelial–mesenchymal transition</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Gene Expression Regulation, Neoplastic</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Molecular Targeted Therapy</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>α-7 Nicotinic acetylcholine receptor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>α7-Nicotinic Acetylcholine Receptor Promotes Cholangiocarcinoma Progression and Epithelial-Mesenchymal Transition Process</dc:title>
        <dcterms:abstract>BACKGROUND: Cholangiocarcinoma is one of the most deadly malignant tumors characterized by a tendency of local invasiveness and metastasis at the early phase, high recurrence rate, and difficulty in treatment. Alpha7-nicotinic acetylcholine receptor (α7-nAChR) is highly expressed in a variety of tumors, including cholangiocarcinoma, and may promote tumor progression, but the mechanisms are largely unknown.
AIMS: Our study is the first to expound upon the role that α7-nAChR plays in cholangiocarcinoma.
METHODS: We assessed 50 human cholangiocarcinoma tissue samples and 20 normal biliary samples using immunohistochemical staining to find the correlation between α7-nAChR expression and clinicopathological characteristics. We used human cholangiocarcinoma cell lines QBC939 and RBE and α7-nAChR gene knockdown RBE cell lines generated by shRNA lentivirus transfection to investigate the biological functions of α7-nAChR in proliferation, apoptosis, migration, and invasiveness in vitro. Further, western blotting was used to detect apoptosis and epithelial-mesenchymal transition (EMT)-related signaling proteins. Cholangiocarcinoma xenografts in nude mice were used for tumorigenicity assays in vivo.
RESULTS: The expression of α7-nAChR was high in cholangiocarcinoma tissues and was closely related to a shorter survival time in patients. α7-nAChR knockdown decreased cell proliferation ability, increased early apoptosis, and weakened cell migration and invasion. Apoptosis-related proteins and components of the EMT process were altered after α7-nAChR knockdown. Moreover, nude mice xenograft experiments confirmed that α7-nAChR could promote cholangiocarcinoma in vitro.
CONCLUSIONS: Overexpression of α7-nAChR induces cholangiocarcinoma progression by blocking apoptosis and promoting the EMT process. As an effective molecular biomarker and prognostic factor, α7-nAChR is a promising therapeutic target in cholangiocarcinoma.</dcterms:abstract>
        <dc:date>2019-10</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 30949902</dc:description>
        <bib:pages>2843-2853</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1573-2568">
        <prism:volume>64</prism:volume>
        <dc:title>Digestive Diseases and Sciences</dc:title>
        <dc:identifier>DOI 10.1007/s10620-019-05609-3</dc:identifier>
        <prism:number>10</prism:number>
        <dcterms:alternative>Dig Dis Sci</dcterms:alternative>
        <dc:identifier>ISSN 1573-2568</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_85">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/30949902</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:25:53</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.nature.com/articles/nprot.2017.016">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1750-2799"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Joung</foaf:surname>
                        <foaf:givenName>Julia</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Konermann</foaf:surname>
                        <foaf:givenName>Silvana</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gootenberg</foaf:surname>
                        <foaf:givenName>Jonathan S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Abudayyeh</foaf:surname>
                        <foaf:givenName>Omar O.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Platt</foaf:surname>
                        <foaf:givenName>Randall J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brigham</foaf:surname>
                        <foaf:givenName>Mark D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sanjana</foaf:surname>
                        <foaf:givenName>Neville E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Feng</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_87"/>
        <link:link rdf:resource="#item_88"/>
        <dc:title>Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening</dc:title>
        <dcterms:abstract>This protocol from Feng Zhang's lab enables genome-scale knockout and transcriptional activation screening using the CRISPR-Cas9 system, as sgRNA libraries are constructed and packaged into lentiviral vectors for delivery into cells for screening.</dcterms:abstract>
        <dc:date>2017-04</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>www.nature.com</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/nprot.2017.016</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:32:54</dcterms:dateSubmitted>
        <dc:rights>2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</dc:rights>
        <dc:description>Bandiera_abtest: a
Cg_type: Nature Research Journals
Number: 4
Primary_atype: Protocols
Publisher: Nature Publishing Group
Subject_term: Genetic engineering;High-throughput screening
Subject_term_id: genetic-engineering;high-throughput-screening</dc:description>
        <bib:pages>828-863</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1750-2799">
        <prism:volume>12</prism:volume>
        <dc:title>Nature Protocols</dc:title>
        <dc:identifier>DOI 10.1038/nprot.2017.016</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Nat Protoc</dcterms:alternative>
        <dc:identifier>ISSN 1750-2799</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_87">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/nprot.2017.016.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:32:56</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_88">
        <z:itemType>attachment</z:itemType>
        <dc:title>Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/nprot.2017.016</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-08 15:33:08</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.sciencedirect.com/science/article/pii/S2405471215002185">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2405-4712"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liberzon</foaf:surname>
                        <foaf:givenName>Arthur</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Birger</foaf:surname>
                        <foaf:givenName>Chet</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Thorvaldsdóttir</foaf:surname>
                        <foaf:givenName>Helga</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ghandi</foaf:surname>
                        <foaf:givenName>Mahmoud</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mesirov</foaf:surname>
                        <foaf:givenName>Jill P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tamayo</foaf:surname>
                        <foaf:givenName>Pablo</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_95"/>
        <link:link rdf:resource="#item_94"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>gene expression</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>gene set enrichment analysis</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>gene sets</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>The Molecular Signatures Database Hallmark Gene Set Collection</dc:title>
        <dcterms:abstract>The Molecular Signatures Database (MSigDB) is one of the most widely used and comprehensive databases of gene sets for performing gene set enrichment analysis. Since its creation, MSigDB has grown beyond its roots in metabolic disease and cancer to include &gt;10,000 gene sets. These better represent a wider range of biological processes and diseases, but the utility of the database is reduced by increased redundancy across, and heterogeneity within, gene sets. To address this challenge, here we use a combination of automated approaches and expert curation to develop a collection of “hallmark” gene sets as part of MSigDB. Each hallmark in this collection consists of a “refined” gene set, derived from multiple “founder” sets, that conveys a specific biological state or process and displays coherent expression. The hallmarks effectively summarize most of the relevant information of the original founder sets and, by reducing both variation and redundancy, provide more refined and concise inputs for gene set enrichment analysis.</dcterms:abstract>
        <dc:date>December 23, 2015</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>ScienceDirect</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.sciencedirect.com/science/article/pii/S2405471215002185</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-22 19:58:25</dcterms:dateSubmitted>
        <bib:pages>417-425</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2405-4712">
        <prism:volume>1</prism:volume>
        <dc:title>Cell Systems</dc:title>
        <dc:identifier>DOI 10.1016/j.cels.2015.12.004</dc:identifier>
        <prism:number>6</prism:number>
        <dcterms:alternative>Cell Systems</dcterms:alternative>
        <dc:identifier>ISSN 2405-4712</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_95">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.cell.com/article/S2405471215002185/pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-22 19:59:05</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_94">
        <z:itemType>attachment</z:itemType>
        <dc:title>ScienceDirect Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.sciencedirect.com/science/article/pii/S2405471215002185</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-22 19:59:00</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267726/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1541-7786"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Matsuo</foaf:surname>
                        <foaf:givenName>Yoichi</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Campbell</foaf:surname>
                        <foaf:givenName>Paul M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brekken</foaf:surname>
                        <foaf:givenName>Rolf A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sung</foaf:surname>
                        <foaf:givenName>Bokyung</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ouellette</foaf:surname>
                        <foaf:givenName>Michel M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fleming</foaf:surname>
                        <foaf:givenName>Jason B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Aggarwal</foaf:surname>
                        <foaf:givenName>Bharat B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Der</foaf:surname>
                        <foaf:givenName>Channing J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guha</foaf:surname>
                        <foaf:givenName>Sushovan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_98"/>
        <link:link rdf:resource="#item_97"/>
        <dc:title>K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways</dc:title>
        <dcterms:abstract>Activating point mutations in the K-Ras oncogene are among the most common genetic alterations in pancreatic cancer, occurring early in the progression of the disease. However, the function of mutant K-Ras activity in tumor angiogenesis remains poorly understood. Using human pancreatic duct epithelial (HPDE) and K-Ras4BG12V–transformed HPDE (HPDE-KRas) cells, we show that activated K-Ras significantly enhanced the production of angiogenic factors including CXC chemokines and vascular endothelial growth factor (VEGF). Western blot analysis revealed that K-Ras activation promoted the phosphorylation of Raf/mitogen-activated protein kinase kinase-1/2 (MEK1/2) and expression of c-Jun. MEK1/2 inhibitors, U0126 and PD98059, significantly inhibited the secretion of both CXC chemokines and VEGF, whereas the c-Jun NH2-terminal kinase inhibitor SP600125 abrogated only CXC chemokine production. To further elucidate the biological functions of oncogenic K-Ras in promoting angiogenesis, we did in vitro invasion and tube formation assays using human umbilical vein endothelial cells (HUVEC). HUVEC cocultured with HPDE-KRas showed significantly enhanced invasiveness and tube formation as compared with either control (without coculture) or coculture with HPDE. Moreover, SB225002 (a CXCR2 inhibitor) and 2C3 (an anti-VEGF monoclonal antibody) either alone or in a cooperative manner significantly reduced the degree of both Ras-dependent HUVEC invasiveness and tube formation. Similar results were obtained using another pair of immortalized human pancreatic duct–derived cells, E6/E7/st and its oncogenic K-Ras variant, E6/E7/Ras/st. Taken together, our results suggest that angiogenesis is initiated by paracrine epithelial secretion of CXC chemokines and VEGF downstream of activated oncogenic K-Ras, and that this vascular maturation is in part dependent on MEK1/2 and c-Jun signaling.</dcterms:abstract>
        <dc:date>2009-6</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267726/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-22 20:08:34</dcterms:dateSubmitted>
        <dc:description>PMID: 19509115
PMCID: PMC4267726</dc:description>
        <bib:pages>799-808</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1541-7786">
        <prism:volume>7</prism:volume>
        <dc:title>Molecular cancer research : MCR</dc:title>
        <dc:identifier>DOI 10.1158/1541-7786.MCR-08-0577</dc:identifier>
        <prism:number>6</prism:number>
        <dcterms:alternative>Mol Cancer Res</dcterms:alternative>
        <dc:identifier>ISSN 1541-7786</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_98">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267726/pdf/nihms645265.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-22 20:08:36</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_97">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267726/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-22 20:08:34</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.nature.com/articles/s41467-020-19288-6">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2041-1723"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hamarsheh</foaf:surname>
                        <foaf:givenName>Shaima’a</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Groß</foaf:surname>
                        <foaf:givenName>Olaf</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brummer</foaf:surname>
                        <foaf:givenName>Tilman</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zeiser</foaf:surname>
                        <foaf:givenName>Robert</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_100"/>
        <link:link rdf:resource="#item_101"/>
        <dc:title>Immune modulatory effects of oncogenic KRAS in cancer</dc:title>
        <dcterms:abstract>Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream signalling is a main driver of carcinogenesis, there is increasing evidence that it also mediates autocrine effects and crosstalk with the tumour microenvironment (TME). Here, we discuss recent reports connecting KRAS mutations with tumour-promoting inflammation and immune modulation caused by KRAS that leads to immune escape in the TME. We discuss the preclinical work on KRAS-induced inflammation and immune modulation in the context of currently ongoing clinical trials targeting cancer entities that carry KRAS mutations and strategies to overcome the oncogene-induced effects on the immune system.</dcterms:abstract>
        <dc:date>2020-10-28</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>www.nature.com</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41467-020-19288-6</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-22 20:09:52</dcterms:dateSubmitted>
        <dc:rights>2020 The Author(s)</dc:rights>
        <dc:description>Bandiera_abtest: a
Cc_license_type: cc_by
Cg_type: Nature Research Journals
Number: 1
Primary_atype: Reviews
Publisher: Nature Publishing Group
Subject_term: Immunosurveillance;Tumour immunology
Subject_term_id: immunosurveillance;tumour-immunology</dc:description>
        <bib:pages>5439</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2041-1723">
        <prism:volume>11</prism:volume>
        <dc:title>Nature Communications</dc:title>
        <dc:identifier>DOI 10.1038/s41467-020-19288-6</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Nat Commun</dcterms:alternative>
        <dc:identifier>ISSN 2041-1723</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_100">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41467-020-19288-6.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-22 20:09:55</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_101">
        <z:itemType>attachment</z:itemType>
        <dc:title>Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41467-020-19288-6</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-22 20:10:07</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_102">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1860-2002"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Stadlbauer</foaf:surname>
                        <foaf:givenName>Andreas</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Roessler</foaf:surname>
                        <foaf:givenName>Karl</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zimmermann</foaf:surname>
                        <foaf:givenName>Max</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Buchfelder</foaf:surname>
                        <foaf:givenName>Michael</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kleindienst</foaf:surname>
                        <foaf:givenName>Andrea</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Doerfler</foaf:surname>
                        <foaf:givenName>Arnd</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heinz</foaf:surname>
                        <foaf:givenName>Gertraud</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Oberndorfer</foaf:surname>
                        <foaf:givenName>Stefan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_103"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Bevacizumab</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Brain Neoplasms</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Female</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Glioblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Male</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Middle Aged</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Disease Progression</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Treatment Outcome</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Angiogenesis</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Antiangiogenic therapy</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Biomarkers, Tumor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Hypoxia</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Magnetic Resonance Imaging</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Recurrence</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Survival Analysis</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Treatment failure</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Treatment monitoring</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tumor microenvironment</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tumor Microenvironment</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>Predicting Glioblastoma Response to Bevacizumab Through MRI Biomarkers of the Tumor Microenvironment</dc:title>
        <dcterms:abstract>PURPOSE: Glioblastoma (GB) is one of the most vascularized of all solid tumors and, therefore, represents an attractive target for antiangiogenic therapies. Many lesions, however, quickly develop escape mechanisms associated with changes in the tumor microenvironment (TME) resulting in rapid treatment failure. To prevent patients from adverse effects of ineffective therapy, there is a strong need to better predict and monitor antiangiogenic treatment response.
PROCEDURES: We utilized a novel physiological magnetic resonance imaging (MRI) method combining the visualization of oxygen metabolism and neovascularization for classification of five different TME compartments: necrosis, hypoxia with/without neovascularization, oxidative phosphorylation, and aerobic glycolysis. This approach, termed TME mapping, was used to monitor changes in tumor biology and pathophysiology within the TME in response to bevacizumab treatment in 18 patients with recurrent GB.
RESULTS: We detected dramatic changes in the TME by rearrangement of its compartments after the onset of bevacizumab treatment. All patients showed a decrease in active tumor volume and neovascularization as well as an increase in hypoxia and necrosis in the first follow-up after 3 months. We found that recurrent GB with a high percentage of neovascularization and active tumor before bevacizumab onset showed a poor or no treatment response.
CONCLUSIONS: TME mapping might be useful to develop strategies for patient stratification and response prediction before bevacizumab onset.</dcterms:abstract>
        <dc:date>2019-08</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 30361791</dc:description>
        <bib:pages>747-757</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1860-2002">
        <prism:volume>21</prism:volume>
        <dc:title>Molecular Imaging and Biology</dc:title>
        <dc:identifier>DOI 10.1007/s11307-018-1289-5</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Mol Imaging Biol</dcterms:alternative>
        <dc:identifier>ISSN 1860-2002</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_103">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/30361791</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 00:03:54</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-06-2072">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0008-5472,%201538-7445"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Maher</foaf:surname>
                        <foaf:givenName>Elizabeth A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brennan</foaf:surname>
                        <foaf:givenName>Cameron</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wen</foaf:surname>
                        <foaf:givenName>Patrick Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Durso</foaf:surname>
                        <foaf:givenName>Laura</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ligon</foaf:surname>
                        <foaf:givenName>Keith L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Richardson</foaf:surname>
                        <foaf:givenName>Aaron</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Khatry</foaf:surname>
                        <foaf:givenName>Deepak</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Feng</foaf:surname>
                        <foaf:givenName>Bin</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sinha</foaf:surname>
                        <foaf:givenName>Raktim</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Louis</foaf:surname>
                        <foaf:givenName>David N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Quackenbush</foaf:surname>
                        <foaf:givenName>John</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Black</foaf:surname>
                        <foaf:givenName>Peter McL.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chin</foaf:surname>
                        <foaf:givenName>Lynda</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>DePinho</foaf:surname>
                        <foaf:givenName>Ronald A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_104"/>
        <dc:title>Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities</dc:title>
        <dc:date>2006-12-01</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-06-2072</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 00:14:59</dcterms:dateSubmitted>
        <bib:pages>11502-11513</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0008-5472,%201538-7445">
        <prism:volume>66</prism:volume>
        <dc:title>Cancer Research</dc:title>
        <dc:identifier>DOI 10.1158/0008-5472.CAN-06-2072</dc:identifier>
        <prism:number>23</prism:number>
        <dcterms:alternative>Cancer Res</dcterms:alternative>
        <dc:identifier>ISSN 0008-5472, 1538-7445</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_104">
        <z:itemType>attachment</z:itemType>
        <dc:title>Maher et al. - 2006 - Marked Genomic Differences Characterize Primary an.pdf</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://d1wqtxts1xzle7.cloudfront.net/47549887/11502-with-cover-page-v2.pdf?Expires=1632359680&amp;Signature=Fxijw7Pi2jFgIkuQ3t8S-as9PHoCeoq8HY3k0YcX~NMXIPf486-xPnLCnD~SzJ4rRJKnO4FSdFRmyel9jgkAn8gq30FtjZ-GVzIrLXfDZork8AGQgVrenLh3AqnTuo-eTppDMW3AiLPcOiGEN3HVlhUIWTExwKQIMC~3ddi5omifmZuBwOPxh85COQOTL-IVBVvUNJoobTo4DorfCH~sjjtjYeBSeL9~ayLmkdpTRU7sa7aLLlzAwD9LhIPqN0PMwJmB0xeni70W39pPFuXVX8sdko55zQ99gOfEO-6cjWTBHVv1UiXR~yqE3EgdDwoxJ94eGWesh3jOLWMJdAoayw__&amp;Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 00:14:53</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_106">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1662-5099"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Karar</foaf:surname>
                        <foaf:givenName>Jayashree</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Maity</foaf:surname>
                        <foaf:givenName>Amit</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_108"/>
        <link:link rdf:resource="#item_107"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>angiogenesis</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>angiopoietins</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>nitric oxide</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>PI3K/AKT/mTOR</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>VEGF</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>PI3K/AKT/mTOR Pathway in Angiogenesis</dc:title>
        <dcterms:abstract>The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is activated in the majority of human cancers. This pathway is known to play a key role in numerous cellular functions including proliferation, adhesion, migration, invasion, metabolism, and survival, but in the current review we focus on its role in angiogenesis. PI3K activation may occur via RAS mutation, loss of phosphatase and tensin homolog (PTEN), or by increased expression of growth factor receptors such as epidermal growth factor receptor. There is a connection between the PI3K pathway and angiogenesis. Hypoxia leads to HIF-1α stabilization and is a major stimulus for increased vascular endothelial growth factor (VEGF) production by tumor cells. However, activation of the PI3K/AKT pathway in tumor cells can also increase VEGF secretion, both by hypoxia-inducible factor 1 (HIF-1) dependent and independent mechanisms. The PI3K/AKT pathway also modulates the expression of other angiogenic factors such as nitric oxide and angiopoietins. Numerous inhibitors targeting the PI3K/AKT/mTOR pathway have been developed, and these agents have been shown to decrease VEGF secretion and angiogenesis. The effect of these inhibitors on tumor vasculature can be difficult to predict. The vasculature of tumors is aberrant, leading to sluggish bloodflow and elevated interstitial blood pressure, which can be perpetuated by the high levels of VEGF. Hence, decreasing VEGF expression can paradoxically lead to vascular normalization and improved bloodflow in some tumors. In addition to its importance in cancer, the PI3K pathway also plays an essential role in the formation of normal blood vessels during development. Embryos with kinase-dead p110α catalytic subunit of PI3K develop vascular defects. Stimulation of endothelial cells by VEGF leads to activation of the PI3K pathway within these cells, which is important for cell migration. Sustained endothelial activation of AKT1 has been shown to induce the formation of structurally abnormal blood vessels that recapitulate the aberrations of tumor vessels. Hence, the PI3K pathway plays an important role in regulating angiogenesis both in normal tissues and in cancers.</dcterms:abstract>
        <dc:date>2011</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 22144946
PMCID: PMC3228996</dc:description>
        <bib:pages>51</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1662-5099">
        <prism:volume>4</prism:volume>
        <dc:title>Frontiers in Molecular Neuroscience</dc:title>
        <dc:identifier>DOI 10.3389/fnmol.2011.00051</dc:identifier>
        <dcterms:alternative>Front Mol Neurosci</dcterms:alternative>
        <dc:identifier>ISSN 1662-5099</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_108">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.frontiersin.org/articles/10.3389/fnmol.2011.00051/pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 17:56:45</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_107">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/22144946</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 17:56:41</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Document rdf:about="http://www.informatics.jax.org/vocab/gene_ontology/GO:0001525">
        <z:itemType>webpage</z:itemType>
        <dcterms:isPartOf>
           <z:Website></z:Website>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_110"/>
        <dc:title>angiogenesis Gene Ontology Term (GO:0001525)</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.informatics.jax.org/vocab/gene_ontology/GO:0001525</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 18:02:09</dcterms:dateSubmitted>
    </bib:Document>
    <z:Attachment rdf:about="#item_110">
        <z:itemType>attachment</z:itemType>
        <dc:title>angiogenesis Gene Ontology Term (GO:0001525)</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.informatics.jax.org/vocab/gene_ontology/GO:0001525</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 18:02:21</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_111">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1539-2864"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Davis</foaf:surname>
                        <foaf:givenName>Stephen J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lyzogubov</foaf:surname>
                        <foaf:givenName>Valeriy V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tytarenko</foaf:surname>
                        <foaf:givenName>Ruslana G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Safar</foaf:surname>
                        <foaf:givenName>Ammar N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bora</foaf:surname>
                        <foaf:givenName>Nalini S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bora</foaf:surname>
                        <foaf:givenName>Puran S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_113"/>
        <link:link rdf:resource="#item_112"/>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Angiogenesis Inhibitors</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Antibodies, Monoclonal, Humanized</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Bevacizumab</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Male</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>alpha7 Nicotinic Acetylcholine Receptor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Animals</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Mice</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Nicotine</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Receptors, Nicotinic</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Adiponectin</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Analysis of Variance</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Bungarotoxins</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Choroid</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Choroidal Neovascularization</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Disease Models, Animal</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Immunohistochemistry</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Intravitreal Injections</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Mice, Inbred C57BL</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Retinal Pigment Epithelium</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Vascular Endothelial Growth Factors</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>The effect of nicotine on anti-vascular endothelial growth factor therapy in a mouse model of neovascular age-related macular degeneration</dc:title>
        <dcterms:abstract>PURPOSE: The purpose of this article is to evaluate the effect of nicotine on anti-vascular endothelial growth factor therapy in the treatment of neovascular age-related macular degeneration.
METHODS: One group of mice received nicotine in drinking water and the other group received water only. Choroidal neovascularization (CNV) was induced with a laser. Nicotinic acetylcholine receptor-α7 (nAChRα7) expression was evaluated by immunohistochemistry. Bevacizumab or adiponectin peptide II (APNpII) was injected intravitreally on Day 7 postlaser, and the effects were evaluated on Days 14 and 21. α-Bungarotoxin was injected intraperitoneally on Days 2 to 5, and its effect was evaluated on Day 14.
RESULTS: Expression of nAChRα7 was 2 to 7 times higher between Days 3 and 7 postlaser compared with naive mice. In water-fed mice, APNpII, bevacizumab, and α-bungarotoxin significantly reduced CNV size. In nicotine-fed mice, treatment with APNpII or bevacizumab did not significantly reduce CNV size, whereas α-bungarotoxin did have an effect. Comparing water- and nicotine-fed mice, CNV size was 61% to 86% smaller in water-fed mice except for the α-bungarotoxin group, where there was no difference. Platelet-derived growth factor and vascular endothelial growth factor expression was 1.5- to 2.5-fold higher at Day 14 in nicotine-treated mice.
CONCLUSION: Nicotine significantly blocks the effect of anti-vascular endothelial growth factor therapy in the treatment of laser-induced neovascular age-related macular degeneration. nAChRα7 is significantly upregulated during the formation of CNV, and treatment with an nAChRα7 antagonist decreases CNV size irrespective of nicotine administration.</dcterms:abstract>
        <dc:date>2012-06</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 22088983
PMCID: PMC3563266</dc:description>
        <bib:pages>1171-1180</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1539-2864">
        <prism:volume>32</prism:volume>
        <dc:title>Retina (Philadelphia, Pa.)</dc:title>
        <dc:identifier>DOI 10.1097/IAE.0b013e31823496b8</dc:identifier>
        <prism:number>6</prism:number>
        <dcterms:alternative>Retina</dcterms:alternative>
        <dc:identifier>ISSN 1539-2864</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_113">
        <z:itemType>attachment</z:itemType>
        <dc:title>Accepted Version</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://europepmc.org/articles/pmc3563266?pdf=render</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:16:35</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_112">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/22088983</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:16:28</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S1043466612008198">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:10434666"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gonzalez</foaf:surname>
                        <foaf:givenName>C.R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vallcaneras</foaf:surname>
                        <foaf:givenName>S.S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Calandra</foaf:surname>
                        <foaf:givenName>R.S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gonzalez Calvar</foaf:surname>
                        <foaf:givenName>S.I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_114"/>
        <dc:title>Involvement of KLF14 and egr-1 in the TGF-beta1 action on Leydig cell proliferation</dc:title>
        <dcterms:abstract>Transforming growth factor b1 (TGF-b1) is a pleiotropic cytokine that modulates cell homeostasis. In Leydig cells, TGF-b1 exerts stimulatory and inhibitory effect depending on the type I receptor involved in the signaling pathway. The aim of the present work was to study the signaling mechanisms and the intermediates involved in the action of TGF-b1 on TM3 Leydig cell proliferation in the presence or absence of progesterone.</dcterms:abstract>
        <dc:date>02/2013</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S1043466612008198</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:23:30</dcterms:dateSubmitted>
        <bib:pages>670-675</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:10434666">
        <prism:volume>61</prism:volume>
        <dc:title>Cytokine</dc:title>
        <dc:identifier>DOI 10.1016/j.cyto.2012.12.009</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Cytokine</dcterms:alternative>
        <dc:identifier>ISSN 10434666</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_114">
        <z:itemType>attachment</z:itemType>
        <dc:title>Gonzalez et al. - 2013 - Involvement of KLF14 and egr-1 in the TGF-beta1 ac.pdf</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://notablesdelaciencia.conicet.gov.ar/bitstream/handle/11336/76459/CONICET_Digital_Nro.0dd38bb2-4e18-4894-a723-85b723b281e7_A.pdf?sequence=2&amp;isAllowed=y</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:23:27</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.nature.com/articles/s41598-021-89754-8">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2045-2322"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lee</foaf:surname>
                        <foaf:givenName>Ji Yun</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenName>Joo Hyun</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bang</foaf:surname>
                        <foaf:givenName>Heejin</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cho</foaf:surname>
                        <foaf:givenName>Junhun</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ko</foaf:surname>
                        <foaf:givenName>Young Hyeh</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenName>Seok Jin</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenName>Won Seog</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_117"/>
        <link:link rdf:resource="#item_118"/>
        <dc:title>EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma</dc:title>
        <dcterms:abstract>Extranodal natural killer T-cell lymphoma (ENKTL) is an aggressive malignancy with a dismal prognosis. In the present study, gene expression profiling was performed to provide more information on ENKTL molecular signature and offer a rationale for further investigation of prognostic markers in ENKTL. NanoString nCounter Analysis encompassing 133 target genes was used to compare gene expression levels of 43 ENKTL tumor samples. The majority of the patients were under 60 years of age (79.1%); 32 (74.4%) patients had nasal type ENKTL and 23 patients (53.5%) had intermediate/high risk ENKTL based on the prognostic index for natural killer cell lymphoma (PINK). The median follow-up was 15.9 months and the median overall survival (OS) was 16.1 months (95% CI 13.0–69.8). EGR1 upregulation was consistently identified in the localized stage with a low risk of prognostic index based on the PINK. Among the six significantly relevant genes for EGR1 expression, high expression levels of genes, including CD59, GAS1, CXCR7, and RAMP3, were associated with a good survival prognosis. The in vitro test showed EGR1 modulated the transcriptional activity of the target genes including CD59, GAS1, CXCR7, and RAMP3. Downregulation of EGR1 and its target genes significantly inhibited apoptosis and decreased chemosensitivity and attenuated radiation-induced apoptosis. The findings showed EGR1 may be a candidate for prognostic markers in ENKTL. Considerable additional characterization may be necessary to fully understand EGR1.</dcterms:abstract>
        <dc:date>2021-05-14</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>www.nature.com</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41598-021-89754-8</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:24:20</dcterms:dateSubmitted>
        <dc:rights>2021 The Author(s)</dc:rights>
        <dc:description>Bandiera_abtest: a
Cc_license_type: cc_by
Cg_type: Nature Research Journals
Number: 1
Primary_atype: Research
Publisher: Nature Publishing Group
Subject_term: Haematological cancer;Tumour biomarkers
Subject_term_id: haematological-cancer;tumour-biomarkers</dc:description>
        <bib:pages>10342</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2045-2322">
        <prism:volume>11</prism:volume>
        <dc:title>Scientific Reports</dc:title>
        <dc:identifier>DOI 10.1038/s41598-021-89754-8</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Sci Rep</dcterms:alternative>
        <dc:identifier>ISSN 2045-2322</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_117">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41598-021-89754-8.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:24:22</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_118">
        <z:itemType>attachment</z:itemType>
        <dc:title>Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41598-021-89754-8</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:24:31</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281832/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0006-4971"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Scheicher</foaf:surname>
                        <foaf:givenName>Ruth</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hoelbl-Kovacic</foaf:surname>
                        <foaf:givenName>Andrea</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bellutti</foaf:surname>
                        <foaf:givenName>Florian</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tigan</foaf:surname>
                        <foaf:givenName>Anca-Sarmiza</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Prchal-Murphy</foaf:surname>
                        <foaf:givenName>Michaela</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heller</foaf:surname>
                        <foaf:givenName>Gerwin</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schneckenleithner</foaf:surname>
                        <foaf:givenName>Christine</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Salazar-Roa</foaf:surname>
                        <foaf:givenName>María</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zöchbauer-Müller</foaf:surname>
                        <foaf:givenName>Sabine</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zuber</foaf:surname>
                        <foaf:givenName>Johannes</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Malumbres</foaf:surname>
                        <foaf:givenName>Marcos</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kollmann</foaf:surname>
                        <foaf:givenName>Karoline</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sexl</foaf:surname>
                        <foaf:givenName>Veronika</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_121"/>
        <link:link rdf:resource="#item_120"/>
        <dc:title>CDK6 as a key regulator of hematopoietic and leukemic stem cell activation</dc:title>
        <dcterms:abstract>CDK6 acts as a transcriptional regulator to suppress Egr1 in HSCs and LSCs, allowing their activation.
            
            
              Cdk6−/− HSCs fail to contribute to repopulation in competitive transplants, and BCR-ABLp210+
Cdk6−/− LSCs fail to inflict disease.
            
          
        , The cyclin-dependent kinase 6 (CDK6) and CDK4 have redundant functions in regulating cell-cycle progression. We describe a novel role for CDK6 in hematopoietic and leukemic stem cells (hematopoietic stem cells [HSCs] and leukemic stem cells [LSCs]) that exceeds its function as a cell-cycle regulator. Although hematopoiesis appears normal under steady-state conditions, Cdk6−/− HSCs do not efficiently repopulate upon competitive transplantation, and Cdk6-deficient mice are significantly more susceptible to 5-fluorouracil treatment. We find that activation of HSCs requires CDK6, which interferes with the transcription of key regulators, including Egr1. Transcriptional profiling of HSCs is consistent with the central role of Egr1. The impaired repopulation capacity extends to BCR-ABLp210+ LSCs. Transplantation with BCR-ABLp210+–infected bone marrow from Cdk6−/− mice fails to induce disease, although recipient mice do harbor LSCs. Egr1 knock-down in Cdk6−/− BCR-ABLp210+ LSKs significantly enhances the potential to form colonies, underlining the importance of the CDK6-Egr1 axis. Our findings define CDK6 as an important regulator of stem cell activation and an essential component of a transcriptional complex that suppresses Egr1 in HSCs and LSCs.</dcterms:abstract>
        <dc:date>2015-1-1</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281832/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:27:21</dcterms:dateSubmitted>
        <dc:description>PMID: 25342715
PMCID: PMC4281832</dc:description>
        <bib:pages>90-101</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0006-4971">
        <prism:volume>125</prism:volume>
        <dc:title>Blood</dc:title>
        <dc:identifier>DOI 10.1182/blood-2014-06-584417</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Blood</dcterms:alternative>
        <dc:identifier>ISSN 0006-4971</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_121">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://ashpublications.org/blood/article-pdf/125/1/90/1383824/90.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:27:24</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_120">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281832/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:27:21</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_122">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1546-170X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Junfei</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Andrew X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gartrell</foaf:surname>
                        <foaf:givenName>Robyn D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Silverman</foaf:surname>
                        <foaf:givenName>Andrew M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Aparicio</foaf:surname>
                        <foaf:givenName>Luis</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chu</foaf:surname>
                        <foaf:givenName>Tim</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bordbar</foaf:surname>
                        <foaf:givenName>Darius</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shan</foaf:surname>
                        <foaf:givenName>David</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Samanamud</foaf:surname>
                        <foaf:givenName>Jorge</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mahajan</foaf:surname>
                        <foaf:givenName>Aayushi</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Filip</foaf:surname>
                        <foaf:givenName>Ioan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Orenbuch</foaf:surname>
                        <foaf:givenName>Rose</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Goetz</foaf:surname>
                        <foaf:givenName>Morgan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yamaguchi</foaf:surname>
                        <foaf:givenName>Jonathan T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cloney</foaf:surname>
                        <foaf:givenName>Michael</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Horbinski</foaf:surname>
                        <foaf:givenName>Craig</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lukas</foaf:surname>
                        <foaf:givenName>Rimas V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Raizer</foaf:surname>
                        <foaf:givenName>Jeffrey</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rae</foaf:surname>
                        <foaf:givenName>Ali I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yuan</foaf:surname>
                        <foaf:givenName>Jinzhou</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Canoll</foaf:surname>
                        <foaf:givenName>Peter</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bruce</foaf:surname>
                        <foaf:givenName>Jeffrey N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Saenger</foaf:surname>
                        <foaf:givenName>Yvonne M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sims</foaf:surname>
                        <foaf:givenName>Peter</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Iwamoto</foaf:surname>
                        <foaf:givenName>Fabio M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sonabend</foaf:surname>
                        <foaf:givenName>Adam M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rabadan</foaf:surname>
                        <foaf:givenName>Raul</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_124"/>
        <link:link rdf:resource="#item_123"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Aged</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Antibodies, Monoclonal, Humanized</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Brain Neoplasms</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Female</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Glioblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Male</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Middle Aged</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Young Adult</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Treatment Outcome</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tumor Microenvironment</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Adult</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Antineoplastic Agents, Immunological</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Gene Expression Profiling</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Genomics</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Immune Tolerance</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Longitudinal Studies</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Mutation</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Nivolumab</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Programmed Cell Death 1 Receptor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
                <rdf:value>Protein Tyrosine Phosphatase, Non-Receptor Type 11</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Proto-Oncogene Proteins B-raf</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>PTEN Phosphohydrolase</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>T-Lymphocytes</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma</dc:title>
        <dcterms:abstract>Immune checkpoint inhibitors have been successful across several tumor types; however, their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where &lt;10% of patients show long-term responses. To understand the molecular determinants of immunotherapeutic response in GBM, we longitudinally profiled 66 patients, including 17 long-term responders, during standard therapy and after treatment with PD-1 inhibitors (nivolumab or pembrolizumab). Genomic and transcriptomic analysis revealed a significant enrichment of PTEN mutations associated with immunosuppressive expression signatures in non-responders, and an enrichment of MAPK pathway alterations (PTPN11, BRAF) in responders. Responsive tumors were also associated with branched patterns of evolution from the elimination of neoepitopes as well as with differences in T cell clonal diversity and tumor microenvironment profiles. Our study shows that clinical response to anti-PD-1 immunotherapy in GBM is associated with specific molecular alterations, immune expression signatures, and immune infiltration that reflect the tumor's clonal evolution during treatment.</dcterms:abstract>
        <dc:date>2019-03</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 30742119
PMCID: PMC6810613</dc:description>
        <bib:pages>462-469</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1546-170X">
        <prism:volume>25</prism:volume>
        <dc:title>Nature Medicine</dc:title>
        <dc:identifier>DOI 10.1038/s41591-019-0349-y</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>Nat Med</dcterms:alternative>
        <dc:identifier>ISSN 1546-170X</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_124">
        <z:itemType>attachment</z:itemType>
        <dc:title>Accepted Version</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://europepmc.org/articles/pmc6810613?pdf=render</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:41:18</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_123">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/30742119</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:41:13</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_125">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1097-4172"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brennan</foaf:surname>
                        <foaf:givenName>Cameron W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Verhaak</foaf:surname>
                        <foaf:givenName>Roel G. W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>McKenna</foaf:surname>
                        <foaf:givenName>Aaron</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Campos</foaf:surname>
                        <foaf:givenName>Benito</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Noushmehr</foaf:surname>
                        <foaf:givenName>Houtan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Salama</foaf:surname>
                        <foaf:givenName>Sofie R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenName>Siyuan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chakravarty</foaf:surname>
                        <foaf:givenName>Debyani</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sanborn</foaf:surname>
                        <foaf:givenName>J. Zachary</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Berman</foaf:surname>
                        <foaf:givenName>Samuel H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Beroukhim</foaf:surname>
                        <foaf:givenName>Rameen</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bernard</foaf:surname>
                        <foaf:givenName>Brady</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Chang-Jiun</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Genovese</foaf:surname>
                        <foaf:givenName>Giannicola</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shmulevich</foaf:surname>
                        <foaf:givenName>Ilya</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Barnholtz-Sloan</foaf:surname>
                        <foaf:givenName>Jill</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zou</foaf:surname>
                        <foaf:givenName>Lihua</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vegesna</foaf:surname>
                        <foaf:givenName>Rahulsimham</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shukla</foaf:surname>
                        <foaf:givenName>Sachet A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ciriello</foaf:surname>
                        <foaf:givenName>Giovanni</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yung</foaf:surname>
                        <foaf:givenName>W. K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Wei</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sougnez</foaf:surname>
                        <foaf:givenName>Carrie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mikkelsen</foaf:surname>
                        <foaf:givenName>Tom</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Aldape</foaf:surname>
                        <foaf:givenName>Kenneth</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bigner</foaf:surname>
                        <foaf:givenName>Darell D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Van Meir</foaf:surname>
                        <foaf:givenName>Erwin G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Prados</foaf:surname>
                        <foaf:givenName>Michael</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sloan</foaf:surname>
                        <foaf:givenName>Andrew</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Black</foaf:surname>
                        <foaf:givenName>Keith L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Eschbacher</foaf:surname>
                        <foaf:givenName>Jennifer</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Finocchiaro</foaf:surname>
                        <foaf:givenName>Gaetano</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Friedman</foaf:surname>
                        <foaf:givenName>William</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Andrews</foaf:surname>
                        <foaf:givenName>David W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guha</foaf:surname>
                        <foaf:givenName>Abhijit</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Iacocca</foaf:surname>
                        <foaf:givenName>Mary</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>O'Neill</foaf:surname>
                        <foaf:givenName>Brian P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Foltz</foaf:surname>
                        <foaf:givenName>Greg</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Myers</foaf:surname>
                        <foaf:givenName>Jerome</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Weisenberger</foaf:surname>
                        <foaf:givenName>Daniel J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Penny</foaf:surname>
                        <foaf:givenName>Robert</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kucherlapati</foaf:surname>
                        <foaf:givenName>Raju</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Perou</foaf:surname>
                        <foaf:givenName>Charles M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hayes</foaf:surname>
                        <foaf:givenName>D. Neil</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gibbs</foaf:surname>
                        <foaf:givenName>Richard</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Marra</foaf:surname>
                        <foaf:givenName>Marco</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mills</foaf:surname>
                        <foaf:givenName>Gordon B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lander</foaf:surname>
                        <foaf:givenName>Eric</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Spellman</foaf:surname>
                        <foaf:givenName>Paul</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wilson</foaf:surname>
                        <foaf:givenName>Richard</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sander</foaf:surname>
                        <foaf:givenName>Chris</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Weinstein</foaf:surname>
                        <foaf:givenName>John</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Meyerson</foaf:surname>
                        <foaf:givenName>Matthew</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gabriel</foaf:surname>
                        <foaf:givenName>Stacey</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Laird</foaf:surname>
                        <foaf:givenName>Peter W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Haussler</foaf:surname>
                        <foaf:givenName>David</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Getz</foaf:surname>
                        <foaf:givenName>Gad</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chin</foaf:surname>
                        <foaf:givenName>Lynda</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                       <foaf:surname>TCGA Research Network</foaf:surname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_127"/>
        <link:link rdf:resource="#item_126"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Brain Neoplasms</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Female</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Glioblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Male</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Signal Transduction</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Gene Expression Profiling</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Mutation</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Gene Regulatory Networks</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Proteome</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>The somatic genomic landscape of glioblastoma</dc:title>
        <dcterms:abstract>We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors, including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer.</dcterms:abstract>
        <dc:date>2013-10-10</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 24120142
PMCID: PMC3910500</dc:description>
        <bib:pages>462-477</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1097-4172">
        <prism:volume>155</prism:volume>
        <dc:title>Cell</dc:title>
        <dc:identifier>DOI 10.1016/j.cell.2013.09.034</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Cell</dcterms:alternative>
        <dc:identifier>ISSN 1097-4172</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_127">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.cell.com/article/S0092867413012087/pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:41:22</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_126">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/24120142</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:41:19</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_128">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1476-4687"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cancer Genome Atlas Research Network</foaf:surname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_130"/>
        <link:link rdf:resource="#item_129"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Aged</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Brain Neoplasms</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Female</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Glioblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Male</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Middle Aged</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Signal Transduction</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Gene Expression Regulation, Neoplastic</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Adult</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Genomics</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Mutation</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Adolescent</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Aged, 80 and over</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>DNA Methylation</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>DNA Modification Methylases</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>DNA Repair</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>DNA Repair Enzymes</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Gene Dosage</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Genes, erbB-1</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Genes, Tumor Suppressor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Genome, Human</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Models, Molecular</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Neurofibromin 1</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Phosphatidylinositol 3-Kinases</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Protein Structure, Tertiary</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Retrospective Studies</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tumor Suppressor Proteins</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>Comprehensive genomic characterization defines human glioblastoma genes and core pathways</dc:title>
        <dcterms:abstract>Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilot project aims to assess the value of large-scale multi-dimensional analysis of these molecular characteristics in human cancer and to provide the data rapidly to the research community. Here we report the interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas--the most common type of adult brain cancer--and nucleotide sequence aberrations in 91 of the 206 glioblastomas. This analysis provides new insights into the roles of ERBB2, NF1 and TP53, uncovers frequent mutations of the phosphatidylinositol-3-OH kinase regulatory subunit gene PIK3R1, and provides a network view of the pathways altered in the development of glioblastoma. Furthermore, integration of mutation, DNA methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated glioblastomas, an observation with potential clinical implications. Together, these findings establish the feasibility and power of TCGA, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer.</dcterms:abstract>
        <dc:date>2008-10-23</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 18772890
PMCID: PMC2671642</dc:description>
        <bib:pages>1061-1068</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1476-4687">
        <prism:volume>455</prism:volume>
        <dc:title>Nature</dc:title>
        <dc:identifier>DOI 10.1038/nature07385</dc:identifier>
        <prism:number>7216</prism:number>
        <dcterms:alternative>Nature</dcterms:alternative>
        <dc:identifier>ISSN 1476-4687</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_130">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/nature07385.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:41:27</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_129">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/18772890</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:41:25</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922765/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1754-2189"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Larson</foaf:surname>
                        <foaf:givenName>Matthew H</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gilbert</foaf:surname>
                        <foaf:givenName>Luke A</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Xiaowo</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lim</foaf:surname>
                        <foaf:givenName>Wendell A</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Weissman</foaf:surname>
                        <foaf:givenName>Jonathan S</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qi</foaf:surname>
                        <foaf:givenName>Lei S</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_133"/>
        <link:link rdf:resource="#item_132"/>
        <dc:title>CRISPR interference (CRISPRi) for sequence-specific control of gene expression</dc:title>
        <dcterms:abstract>Sequence-specific control of gene expression on a genome-wide scale is an
important approach for understanding gene functions and for engineering genetic
regulatory systems. We have recently described an RNA-based method, CRISPR
interference (CRISPRi), for targeted silencing of transcription in bacteria and
human cells. The CRISPRi system is derived from the Streptococcus
pyogenes CR ISPR (clustered regularly interspaced palindromic
repeats) pathway, requiring only the coexpression of a catalytically inactive
Cas9 protein and a customizable single guide RNA (sgRNA ). The Cas9-sgRNA
complex binds to DNA elements complementary to the sgRNA and causes a steric
block that halts transcript elongation by RNA polymerase, resulting in the
repression of the target gene. Here we provide a protocol for the design,
construction and expression of customized sgRNA s for transcriptional repression
of any gene of interest. We also provide details for testing the repression
activity of CRISPRi using quantitative fluorescence assays and native elongating
transcript sequencing. CRISPRi provides a simplified approach for rapid gene
repression within 1–2 weeks. The method can also be adapted for
high-throughput interrogation of genome-wide gene functions and genetic
interactions, thus providing a complementary approach to RNA interference, which
can be used in a wider variety of organisms.</dcterms:abstract>
        <dc:date>2013-11</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922765/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:59:25</dcterms:dateSubmitted>
        <dc:description>PMID: 24136345
PMCID: PMC3922765</dc:description>
        <bib:pages>2180-2196</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1754-2189">
        <prism:volume>8</prism:volume>
        <dc:title>Nature protocols</dc:title>
        <dc:identifier>DOI 10.1038/nprot.2013.132</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>Nat Protoc</dcterms:alternative>
        <dc:identifier>ISSN 1754-2189</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_133">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922765/pdf/nihms548924.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:59:27</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_132">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922765/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2021-09-23 19:59:25</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_500">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0735-1097"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Link</foaf:surname>
                        <foaf:givenName>Mark S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hellkamp</foaf:surname>
                        <foaf:givenName>Anne S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Estes</foaf:surname>
                        <foaf:givenName>N. A. Mark</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Orav</foaf:surname>
                        <foaf:givenName>E. John</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ellenbogen</foaf:surname>
                        <foaf:givenName>Kenneth A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ibrahim</foaf:surname>
                        <foaf:givenName>Bassiema</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Greenspon</foaf:surname>
                        <foaf:givenName>Arnold</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rizo-Patron</foaf:surname>
                        <foaf:givenName>Carlos</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Goldman</foaf:surname>
                        <foaf:givenName>Lee</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lee</foaf:surname>
                        <foaf:givenName>Kerry L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lamas</foaf:surname>
                        <foaf:givenName>Gervasio A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                       <foaf:surname>MOST Study Investigators</foaf:surname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_501"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Aged</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Female</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Male</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Treatment Outcome</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Cardiac Pacing, Artificial</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Follow-Up Studies</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Incidence</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Randomized Controlled Trials as Topic</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Sick Sinus Syndrome</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Syncope</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Syndrome</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based pacing in the Mode Selection Trial (MOST)</dc:title>
        <dcterms:abstract>OBJECTIVES: We evaluated the incidence, predictors, and treatment of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based (VVIR) pacing in the Mode Selection Trial (MOST).
BACKGROUND: Pacemaker syndrome, or intolerance to VVIR pacing, consists of cardiovascular signs and symptoms induced by VVIR pacing.
METHODS: The definition of pacemaker syndrome required that a patient with single-chamber VVIR pacing develop either congestive signs and symptoms associated with retrograde conduction during VVIR pacing or a &gt;or=20 mm Hg reduction of systolic blood pressure during VVIR pacing, associated with reproducible symptoms of weakness, lightheadedness, or syncope.
RESULTS: Of 996 patients randomized to VVIR pacing, 182 (18.3%) met criteria for pacemaker syndrome in follow-up. Pacemaker syndrome occurred early in most patients (13.8% at 6 months, 16.0% at 1 year, increasing to 19.7% at 4 years). Baseline univariate predictors of pacemaker syndrome included a lower sinus rate and higher programmed pacemaker rate. Previous heart failure, ejection fraction, and drop in systolic blood pressure with VVIR pacing at implantation did not predict the development of pacemaker syndrome. Post-implantation predictors of pacemaker syndrome were a higher percentage of paced beats, higher programmed low rate, and slower underlying spontaneous sinus rate. Quality of life decreased at the time of diagnosis of pacemaker syndrome and improved with reprogramming to atrial-based pacing.
CONCLUSIONS: Severe pacemaker syndrome developed in nearly 20% of VVIR-paced patients and improved with reprogramming to the dual-chamber pacing mode. Because prediction of pacemaker syndrome is difficult, the only way to prevent pacemaker syndrome is to implant atrial-based pacemakers in all patients.</dcterms:abstract>
        <dc:date>2004-06-02</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 15172414</dc:description>
        <bib:pages>2066-2071</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0735-1097">
        <prism:volume>43</prism:volume>
        <dc:title>Journal of the American College of Cardiology</dc:title>
        <dc:identifier>DOI 10.1016/j.jacc.2003.10.072</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>J Am Coll Cardiol</dcterms:alternative>
        <dc:identifier>ISSN 0735-1097</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_501">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/15172414</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-01-27 14:53:39</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5331352/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>16</prism:volume>
                <dc:title>Anatolian Journal of Cardiology</dc:title>
                <dc:identifier>DOI 10.5152/AnatolJCardiol.2015.6515</dc:identifier>
                <prism:number>9</prism:number>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bellmann</foaf:surname>
                        <foaf:givenName>Barbara</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Muntean</foaf:surname>
                        <foaf:givenName>Bogdan G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lin</foaf:surname>
                        <foaf:givenName>Tina</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gemein</foaf:surname>
                        <foaf:givenName>Christopher</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schmitz</foaf:surname>
                        <foaf:givenName>Kathrin</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schauerte</foaf:surname>
                        <foaf:givenName>Patrick</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:title>Late deterioration of left ventricular function after right ventricular pacemaker implantation</dc:title>
        <dcterms:abstract>Right ventricular (RV) pacing induces a left bundle branch block pattern on ECG and may promote heart failure. Patients with dual chamber pacemakers (DCPs) who present with progressive reduction in left ventricular ejection fraction (LVEF) secondary to ...</dcterms:abstract>
        <dc:date>September 2016</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>www.ncbi.nlm.nih.gov</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5331352/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-01-27 14:55:39</dcterms:dateSubmitted>
        <dc:description>Publisher: Turkish Society of Cardiology
PMID: 27488751</dc:description>
        <bib:pages>678</bib:pages>
    </bib:Article>
    <bib:Article rdf:about="#item_666">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1861-387X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tsutsui</foaf:surname>
                        <foaf:givenName>Takeyoshi</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Arakawa</foaf:surname>
                        <foaf:givenName>Yoshiki</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Makino</foaf:surname>
                        <foaf:givenName>Yasuhide</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kataoka</foaf:surname>
                        <foaf:givenName>Hiroharu</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mineharu</foaf:surname>
                        <foaf:givenName>Yohei</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Naito</foaf:surname>
                        <foaf:givenName>Kentaro</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Minamiguchi</foaf:surname>
                        <foaf:givenName>Sachiko</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hirose</foaf:surname>
                        <foaf:givenName>Takanori</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nobusawa</foaf:surname>
                        <foaf:givenName>Sumihito</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nakano</foaf:surname>
                        <foaf:givenName>Yoshiko</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ichimura</foaf:surname>
                        <foaf:givenName>Koichi</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Haga</foaf:surname>
                        <foaf:givenName>Hironori</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Miyamoto</foaf:surname>
                        <foaf:givenName>Susumu</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_681"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Male</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Adult</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tumor Suppressor Proteins</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Astroblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>BEN domain-containing 2 (BEND2)</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
                <rdf:value>CNS high-grade neuroepithelial tumor with MN1 alteration (HGNET-MN1)</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Contrast Media</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
                <rdf:value>Ewing Sarcoma breakpoint region 1/EWS RNA-binding protein 1 (EWSR1)</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>EWSR1-BEND2 fusion</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Gadolinium</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>In Situ Hybridization, Fluorescence</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Methylation</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Neoplasms, Neuroepithelial</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>RNA-Binding Protein EWS</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Spinal Cord</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Trans-Activators</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>Spinal cord astroblastoma with EWSR1-BEND2 fusion classified as HGNET-MN1 by methylation classification: a case report</dc:title>
        <dcterms:abstract>The most recurrent fusion of central nervous system high-grade neuroepithelial tumor with MN1 alteration (HGNET-MN1) is MN1 rearrangement. Here, we report the case of a 36-year-old man with spinal cord astroblastoma showing Ewing Sarcoma breakpoint region 1/EWS RNA-binding protein 1 (EWSR1)-BEN domain-containing 2 (BEND2) fusion. The patient presented with back pain, gait disturbance and dysesthesia in the lower extremities and trunk. Magnetic resonance imaging showed an intramedullary tumor at the T3-5 level, displaying homogeneous gadolinium enhancement. Partial tumor removal was performed with laminectomy. Histological examinations demonstrated solid growth of epithelioid tumor cells showing high cellularity, a pseudopapillary structure, intervening hyalinized fibrous stroma, and some mitoses. Astroblastoma was diagnosed, classified as HGNET-MN1 by the German Cancer Research Center methylation classifier. MN1 alteration was not detected by fluorescence in situ hybridization (FISH), but EWSR1-BEND2 fusion was detected by FISH and RNA sequencing. Previously, a child with EWSR1-BEND2 fusion-positive spinal astroblastoma classified as HGNET-MN1 was reported. In conjunction with that, the present case provides evidence that EWSR1-BEND2 fusion is identified in the entity of HGNET-MN1. Taken together, the BEND2 alteration rather than MN1 may determine the biology of a subset of the central nervous system HGNET-MN1 subclass.</dcterms:abstract>
        <dc:date>2021-10</dc:date>
        <z:language>eng</z:language>
        <z:shortTitle>Spinal cord astroblastoma with EWSR1-BEND2 fusion classified as HGNET-MN1 by methylation classification</z:shortTitle>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 34313881</dc:description>
        <bib:pages>283-289</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1861-387X">
        <prism:volume>38</prism:volume>
        <dc:title>Brain Tumor Pathology</dc:title>
        <dc:identifier>DOI 10.1007/s10014-021-00412-3</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Brain Tumor Pathol</dcterms:alternative>
        <dc:identifier>ISSN 1861-387X</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_681">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/34313881</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-02-10 18:00:44</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://onlinelibrary.wiley.com/doi/abs/10.1111/neup.12514">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1440-1789"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shin</foaf:surname>
                        <foaf:givenName>Sun Ah</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ahn</foaf:surname>
                        <foaf:givenName>Bokyung</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenName>Seung-Ki</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kang</foaf:surname>
                        <foaf:givenName>Hyoung Jin</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nobusawa</foaf:surname>
                        <foaf:givenName>Sumihito</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Komori</foaf:surname>
                        <foaf:givenName>Takashi</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Park</foaf:surname>
                        <foaf:givenName>Sung-Hye</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_682"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>astroblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>gene rearrangement</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>glioma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>MN1</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>ultrastructure</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>Brainstem astroblastoma with MN1 translocation</dc:title>
        <dcterms:abstract>Astroblastoma is a rare glial neoplasm that occurs mostly in the cerebral hemisphere of children, adolescents and young adults. Although astroblastic perivascular pseudorosettes are unique histopathology of this neoplasm, diagnosis is usually challenging. Recently, it was discovered that the meningioma 1 gene (MN1)-altered pediatric central nervous system high-grade neuroepithelial tumors are actually astroblastomas. This case report presents a rare brainstem astroblastoma, with an unusual immunoprofile: negative for glial fibrillary acidic protein and oligodendrocyte transcription factor 2, but with a robust expression of pancytokeratin and epithelial membrane antigen. The diagnosis was confirmed based on the detection of MN1 rearrangement in a fluorescence in situ hybridization study, in addition to typical histopathology. Here we discuss the diagnostic pitfalls and unclear grading system along with a literature review.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>Wiley Online Library</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://onlinelibrary.wiley.com/doi/abs/10.1111/neup.12514</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-02-10 18:00:18</dcterms:dateSubmitted>
        <dc:description>_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/neup.12514</dc:description>
        <bib:pages>631-637</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1440-1789">
        <prism:volume>38</prism:volume>
        <dc:title>Neuropathology</dc:title>
        <dc:identifier>DOI 10.1111/neup.12514</dc:identifier>
        <prism:number>6</prism:number>
        <dc:identifier>ISSN 1440-1789</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_682">
        <z:itemType>attachment</z:itemType>
        <rdf:resource rdf:resource="C:\Users\lodhar\OneDrive - case.edu\Zotero\Shin et al_2018_Brainstem astroblastoma with MN1 translocation.pdf"/>
        <dc:title>Shin et al_2018_Brainstem astroblastoma with MN1 translocation.pdf</dc:title>
        <z:linkMode>2</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_669">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>37</prism:volume>
                <dc:title>Brain Tumor Pathology</dc:title>
                <dc:identifier>DOI 10.1007/s10014-020-00372-0</dc:identifier>
                <prism:number>4</prism:number>
                <dcterms:alternative>Brain Tumor Pathol</dcterms:alternative>
                <dc:identifier>ISSN 1861-387X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Wanwan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Soon</foaf:surname>
                        <foaf:givenName>Yu Yang</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pratiseyo</foaf:surname>
                        <foaf:givenName>Patricia Diana</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sutanto</foaf:surname>
                        <foaf:givenName>Ratna</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hendriansyah</foaf:surname>
                        <foaf:givenName>Lutfi</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kuick</foaf:surname>
                        <foaf:givenName>Chik Hong</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chang</foaf:surname>
                        <foaf:givenName>Kenneth T. E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>Char Loo</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_683"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Female</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Prognosis</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tumor Suppressor Proteins</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Meta-analysis</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Child</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Astroblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Neoplasms, Neuroepithelial</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Trans-Activators</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>MN1</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Age Factors</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Central Nervous System Neoplasms</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>CNS HGNET-MN1</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Neuroectodermal Tumors, Primitive</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Primitive neuroepithelial tumor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Sex Factors</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:title>Central nervous system neuroepithelial tumors with MN1-alteration: an individual patient data meta-analysis of 73 cases</dc:title>
        <dcterms:abstract>MN1 alteration characterizes a recently described group of neuroepithelial tumors with varied morphological features. In cIMPACT-NOW update 6, only those with astroblastoma morphology has been accepted as a newly recognized tumor type, whereas the rest of morphological variants are considered lesions sub-judice. We perform an individual patient data meta-analysis of MN1-altered neuroepithelial tumors comprising a total of 73 cases, in order to study the survival data and predictive markers for better diagnosis and management of this rare molecular entity. The 5- and 10-year progression-free survival are 38% and 0%, whereas the 5- and 10-year overall survival are 89% and 55%, respectively. Among all the morphological variants of MN1-altered tumor, astroblastoma morphology is significantly associated with an improved overall survival, emphasizing the importance of providing an integrated histologic and molecular diagnosis. Histological grading within the molecularly-defined MN1-altered astroblastoma remains controversial. In tumors with astroblastoma morphology, the odds of MN1-altered status among patients less than 15-year-old is 10.5 times that of those 15-year-old and older, and female of 9.4 times that of the male gender. Gross tumor resection appears as main treatment modality for better disease control based on observational data.</dcterms:abstract>
        <dc:date>2020-10</dc:date>
        <z:language>eng</z:language>
        <z:shortTitle>Central nervous system neuroepithelial tumors with MN1-alteration</z:shortTitle>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 32601775</dc:description>
        <bib:pages>145-153</bib:pages>
    </bib:Article>
    <z:Attachment rdf:about="#item_683">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/32601775</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-02-10 15:30:48</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_670">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1433-0350"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sari</foaf:surname>
                        <foaf:givenName>Ramazan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Altinoz</foaf:surname>
                        <foaf:givenName>Meric A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ozyar</foaf:surname>
                        <foaf:givenName>Enis</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Danyeli</foaf:surname>
                        <foaf:givenName>Ayca Ersen</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Elmaci</foaf:surname>
                        <foaf:givenName>Ilhan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_684"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Brain Neoplasms</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Female</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Neoplasm Recurrence, Local</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tumor Suppressor Proteins</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Child</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Astroblastoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Neoplasms, Neuroepithelial</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Trans-Activators</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Carcinoma</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>HGNET</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Meningioma-1</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Metastatic mimicry</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>A pediatric cerebral tumor with MN1 alteration and pathological features mimicking carcinoma metastasis: may the terminology &quot;high grade neuroepithelial tumor with MN1 alteration&quot; still be relevant?</dc:title>
        <dcterms:abstract>INTRODUCTION: Astroblastoma, MN1-altered (old name: high-grade neuroepithelial tumor/HGNET with MN1 alteration) is a recently described central nervous system tumor mostly affecting pediatric patients and profoundly young girls. Differential pathological diagnoses of these tumors include ependymoma, pleomorphic xanthoastrocytoma, embryonal tumor with multilayered rosettes, meningioma, and even glioblastoma. As the treatment approaches to these tumors differ, it is essential to increase the awareness about these tumors in the neurosurgical community.
CLINICAL PRESENTATION: A 7-year-old female patient admitted with a 7-day history of headache, nausea, and vomiting. A contrasted MRI scan revealed a left parietal 4 × 4 × 5 cm mass with central necrosis and peripheral contrast enhancement. The tumor's histopathological findings were suggestive of a metastatic carcinoma with unknown primary, yet further genetic analysis revealed MN1 alteration. Peculiarly, the tumor pathomorphological features were not compatible with astroblastomas and exerted features strongly indicating a metastatic cancer; however, systemic PET and whole-body MRI failed to detect a primary malignancy.
OUTCOME AND CONCLUSIONS: Eighteen months after gross-total tumor resection, an in-field and out-field multifocal recurrence developed which required a second surgery and subsequent chemo-radiotherapy. The patient is doing well for 1 year after the second treatment regimen at the time of this report. Despite the final cIMPACT6 classification in 2020 advised to define all MN1 altered brain tumors as astroblastomas, there exist prognostic differences in MN1-altered tumors with and without morphological features of astroblastoma. Rare morphological variants of MN1-altered tumors shall be recognized for their future prognostic and clinical classification. HGNET with MN1 alteration seems still be a more proper definition of such malignancies as an umbrella term.</dcterms:abstract>
        <dc:date>2021-10</dc:date>
        <z:language>eng</z:language>
        <z:shortTitle>A pediatric cerebral tumor with MN1 alteration and pathological features mimicking carcinoma metastasis</z:shortTitle>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 34269865</dc:description>
        <bib:pages>2967-2974</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1433-0350">
        <prism:volume>37</prism:volume>
        <dc:title>Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery</dc:title>
        <dc:identifier>DOI 10.1007/s00381-021-05289-3</dc:identifier>
        <prism:number>10</prism:number>
        <dcterms:alternative>Childs Nerv Syst</dcterms:alternative>
        <dc:identifier>ISSN 1433-0350</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_684">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/34269865</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-02-10 15:04:35</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://doi.org/10.1007/s10014-019-00346-x">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>36</prism:volume>
                <dc:title>Brain Tumor Pathology</dc:title>
                <dc:identifier>DOI 10.1007/s10014-019-00346-x</dc:identifier>
                <prism:number>3</prism:number>
                <dcterms:alternative>Brain Tumor Pathol</dcterms:alternative>
                <dc:identifier>ISSN 1861-387X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mhatre</foaf:surname>
                        <foaf:givenName>Radhika</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sugur</foaf:surname>
                        <foaf:givenName>Harsha S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nandeesh</foaf:surname>
                        <foaf:givenName>B. N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chickabasaviah</foaf:surname>
                        <foaf:givenName>Yasha</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Saini</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Santosh</foaf:surname>
                        <foaf:givenName>Vani</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_685"/>
        <dc:title>MN1 rearrangement in astroblastoma: study of eight cases and review of literature</dc:title>
        <dcterms:abstract>Astroblastomas are unique tumours with unresolved issues in terms of their origin, molecular biology, clinical behaviour, and response to treatment. To decipher the characteristics of this tumour, we reviewed cases histologically diagnosed as astroblastoma in our institute over the past 8 years, with immunohistochemistry, and performed fluorescence in situ hybridisation (FISH), for the newly emerged MN1 rearrangement which was reported in central nervous system high-grade neuroepithelial tumours. The mean age at diagnosis was 18.6 years with all cases seen in females and with supratentorial localisation. The tumours showed typical circumscription and bubbly appearance on imaging. The cohort included eight cases diagnosed as astroblastoma (two low grades; six anaplastic) based on histology and proliferative index. The tumours displayed characteristic astroblastic pseudorosettes with hyalinised vascular core and variable immunopositivity for glial fibrillary acidic protein, pan cytokeratin, and epithelial membrane antigen. MN1 break-apart by FISH was found in 5/8 of our cases (62.5%), which included 2 low-grade and 3 anaplastic tumours. Tumour recurrence was noted in three cases, with MN1 alteration in two. We account for one of the few series to study the MN1 rearrangement in astroblastoma and conclude that MN1 alteration is seen in a subset of these tumours.</dcterms:abstract>
        <dc:date>2019-07-01</dc:date>
        <z:language>en</z:language>
        <z:shortTitle>MN1 rearrangement in astroblastoma</z:shortTitle>
        <z:libraryCatalog>Springer Link</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>https://doi.org/10.1007/s10014-019-00346-x</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-02-10 14:54:05</dcterms:dateSubmitted>
        <bib:pages>112-120</bib:pages>
    </bib:Article>
    <z:Attachment rdf:about="#item_685">
        <z:itemType>attachment</z:itemType>
        <rdf:resource rdf:resource="C:\Users\lodhar\OneDrive - case.edu\Zotero\Mhatre et al_2019_MN1 rearrangement in astroblastoma.pdf"/>
        <dc:title>Mhatre et al_2019_MN1 rearrangement in astroblastoma.pdf</dc:title>
        <z:linkMode>2</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="#item_838">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0892-6638"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Neufeld</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cohen</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gengrinovitch</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Poltorak</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_839"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Humans</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Vascular Endothelial Growth Factor A</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Animals</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Neovascularization, Physiologic</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Vascular Endothelial Growth Factors</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Alternative Splicing</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Cell Membrane</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Endothelial Growth Factors</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Heparan Sulfate Proteoglycans</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
           <z:AutomaticTag><rdf:value>Lymphokines</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Receptor Protein-Tyrosine Kinases</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Receptors, Growth Factor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
                <rdf:value>Receptors, Vascular Endothelial Growth Factor</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>Vascular endothelial growth factor (VEGF) and its receptors</dc:title>
        <dcterms:abstract>Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular endothelial cells. Five VEGF isoforms are generated as a result of alternative splicing from a single VEGF gene. These isoforms differ in their molecular mass and in biological properties such as their ability to bind to cell-surface heparan-sulfate proteoglycans. The expression of VEGF is potentiated in response to hypoxia, by activated oncogenes, and by a variety of cytokines. VEGF induces endothelial cell proliferation, promotes cell migration, and inhibits apoptosis. In vivo VEGF induces angiogenesis as well as permeabilization of blood vessels, and plays a central role in the regulation of vasculogenesis. Deregulated VEGF expression contributes to the development of solid tumors by promoting tumor angiogenesis and to the etiology of several additional diseases that are characterized by abnormal angiogenesis. Consequently, inhibition of VEGF signaling abrogates the development of a wide variety of tumors. The various VEGF forms bind to two tyrosine-kinase receptors, VEGFR-1 (flt-1) and VEGFR-2 (KDR/flk-1), which are expressed almost exclusively in endothelial cells. Endothelial cells express in addition the neuropilin-1 and neuropilin-2 coreceptors, which bind selectively to the 165 amino acid form of VEGF (VEGF165). This review focuses on recent developments that have widened considerably our understanding of the mechanisms that control VEGF production and VEGF signal transduction and on recent studies that have shed light on the mechanisms by which VEGF regulates angiogenesis.</dcterms:abstract>
        <dc:date>1999-01</dc:date>
        <z:language>eng</z:language>
        <z:libraryCatalog>PubMed</z:libraryCatalog>
        <dc:description>PMID: 9872925</dc:description>
        <bib:pages>9-22</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0892-6638">
        <prism:volume>13</prism:volume>
        <dc:title>FASEB journal: official publication of the Federation of American Societies for Experimental Biology</dc:title>
        <prism:number>1</prism:number>
        <dcterms:alternative>FASEB J</dcterms:alternative>
        <dc:identifier>ISSN 0892-6638</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_839">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed entry</dc:title>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://www.ncbi.nlm.nih.gov/pubmed/9872925</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:41:12</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717957/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0366-6999"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>Ge</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Ying-Jie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guan</foaf:surname>
                        <foaf:givenName>Yan-Jun</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dong</foaf:surname>
                        <foaf:givenName>Da-Peng</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>Gang</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Dan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hao</foaf:surname>
                        <foaf:givenName>Rui-Min</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>Hui-Ru</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Ming</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Kun-Peng</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Shi-Xiang</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Qin-Wen</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Shi-Kai</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zeng</foaf:surname>
                        <foaf:givenName>Yan-Jun</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_842"/>
        <link:link rdf:resource="#item_841"/>
        <dc:title>Relief Effect of Bevacizumab on Severe Edema Induced by Re-irradiation in Brain Tumor Patients</dc:title>
        <dc:date>2015-8-05</dc:date>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717957/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:42:48</dcterms:dateSubmitted>
        <dc:description>PMID: 26228232
PMCID: PMC4717957</dc:description>
        <bib:pages>2126-2129</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0366-6999">
        <prism:volume>128</prism:volume>
        <dc:title>Chinese Medical Journal</dc:title>
        <dc:identifier>DOI 10.4103/0366-6999.161403</dc:identifier>
        <prism:number>15</prism:number>
        <dcterms:alternative>Chin Med J (Engl)</dcterms:alternative>
        <dc:identifier>ISSN 0366-6999</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_842">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717957/pdf/CMJ-128-2126.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:42:55</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_841">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717957/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:42:54</dcterms:dateSubmitted>
        <z:linkMode>3</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.nature.com/articles/s41598-021-85385-1">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>11</prism:volume>
                <dc:title>Scientific Reports</dc:title>
                <dc:identifier>DOI 10.1038/s41598-021-85385-1</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Sci Rep</dcterms:alternative>
                <dc:identifier>ISSN 2045-2322</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Carvalho</foaf:surname>
                        <foaf:givenName>Bruno</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lopes</foaf:surname>
                        <foaf:givenName>José Manuel</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Silva</foaf:surname>
                        <foaf:givenName>Roberto</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Peixoto</foaf:surname>
                        <foaf:givenName>Joana</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Leitão</foaf:surname>
                        <foaf:givenName>Dina</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Soares</foaf:surname>
                        <foaf:givenName>Paula</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fernandes</foaf:surname>
                        <foaf:givenName>Ana Catarina</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Linhares</foaf:surname>
                        <foaf:givenName>Paulo</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vaz</foaf:surname>
                        <foaf:givenName>Rui</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lima</foaf:surname>
                        <foaf:givenName>Jorge</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_844"/>
        <link:link rdf:resource="#item_845"/>
        <dc:subject>
           <z:AutomaticTag><rdf:value>CNS cancer</rdf:value></z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tumour angiogenesis</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:subject>
            <z:AutomaticTag>
               <rdf:value>Tumour biomarkers</rdf:value>
            </z:AutomaticTag>
        </dc:subject>
        <dc:title>The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab</dc:title>
        <dcterms:abstract>Dismal prognosis of glioblastoma (GBM) prompts for the identification of response predictors and therapeutic resistance mechanisms of current therapies. The authors investigated the impact of c-Met, HGF, VEGFR2 expression and microvessel density (MVD) in GBM patients submitted to second-line chemotherapy with bevacizumab. Immunohistochemical expression of c-Met, HGF, VEGFR2, and MVD was assessed in tumor specimens of GBM patients treated with bevacizumab, after progression under temozolomide. Survival analysis was evaluated according to the expression of the aforementioned biomarkers. c-Met overexpression was associated with a time-to-progression (TTP) after bevacizumab of 3 months (95% CI, 1.5–4.5) compared with a TTP of 7 months (95% CI, 4.6–9.4) in patients with low or no expression of c-Met (p = 0.05). VEGFR2 expression was associated with a TTP after bevacizumab of 3 months (95% CI, 1.8–4.2) compared with a TTP of 7 months (95% CI, 5.7–8.3) in patients with no tumoral expression of VEGFR2 (p = 0.009). Concomitant c-Met/VEGFR2 overexpression was associated with worse overall survival (13 months) compared with concomitant c-Met/VEGFR2 negative expression (19 months; p = 0.025). Our data support the hypothesis that c-Met and VEGFR2 overexpression have a role in the development of glioblastoma early resistance and might predict poorer responses to anti-angiogenic therapies.</dcterms:abstract>
        <dc:date>2021-03-16</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>www.nature.com</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41598-021-85385-1</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:43:50</dcterms:dateSubmitted>
        <dc:rights>2021 The Author(s)</dc:rights>
        <dc:description>Number: 1
Publisher: Nature Publishing Group</dc:description>
        <bib:pages>6067</bib:pages>
    </bib:Article>
    <z:Attachment rdf:about="#item_844">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41598-021-85385-1.pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:43:57</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_845">
        <z:itemType>attachment</z:itemType>
        <dc:title>Snapshot</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41598-021-85385-1</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:44:09</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.frontiersin.org/article/10.3389/fonc.2020.00221">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2234-943X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Haibe</foaf:surname>
                        <foaf:givenName>Yolla</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kreidieh</foaf:surname>
                        <foaf:givenName>Malek</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>El Hajj</foaf:surname>
                        <foaf:givenName>Hiba</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Khalifeh</foaf:surname>
                        <foaf:givenName>Ibrahim</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mukherji</foaf:surname>
                        <foaf:givenName>Deborah</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Temraz</foaf:surname>
                        <foaf:givenName>Sally</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shamseddine</foaf:surname>
                        <foaf:givenName>Ali</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_847"/>
        <dc:title>Resistance Mechanisms to Anti-angiogenic Therapies in Cancer</dc:title>
        <dcterms:abstract>Tumor growth and metastasis rely on tumor vascular network for the adequate supply of oxygen and nutrients. Tumor angiogenesis relies on a highly complex program of growth factor signaling, endothelial cell (EC) proliferation, extracellular matrix (ECM) remodeling, and stromal cell interactions. Numerous pro-angiogenic drivers have been identified, the most important of which is the vascular endothelial growth factor (VEGF). The importance of pro-angiogenic inducers in tumor growth, invasion and extravasation make them an excellent therapeutic target in several types of cancers. Hence, the number of anti-angiogenic agents developed for cancer treatment has risen over the past decade, with at least eighty drugs being investigated in preclinical studies and phase I-III clinical trials. To date, the most common approaches to the inhibition of the VEGF axis include the blockade of VEGF receptors (VEGFRs) or ligands by neutralizing antibodies, as well as the inhibition of receptor tyrosine kinase (RTK) enzymes. Despite promising preclinical results, anti-angiogenic monotherapies led only to mild clinical benefits. The minimal benefits could be secondary to primary or acquired resistance, through the activation of alternative mechanisms that sustain tumor vascularization and growth. Mechanisms of resistance are categorized into VEGF-dependent alterations, non-VEGF pathways and stromal cell interactions. Thus, complementary approaches such as the combination of these inhibitors with agents targeting alternative mechanisms of blood vessel formation are urgently needed. This review provides an updated overview on the pathophysiology of angiogenesis during tumor growth. It also sheds light on the different pro-angiogenic and anti-angiogenic agents that have been developed to date. Finally, it highlights the preclinical evidence for mechanisms of angiogenic resistance and suggests novel therapeutic approaches that might be exploited with the ultimate aim of overcoming resistance and improving clinical outcomes for patients with cancer.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:libraryCatalog>Frontiers</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.frontiersin.org/article/10.3389/fonc.2020.00221</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:46:41</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2234-943X">
        <prism:volume>10</prism:volume>
        <dc:title>Frontiers in Oncology</dc:title>
        <dc:identifier>ISSN 2234-943X</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_847">
        <z:itemType>attachment</z:itemType>
        <dc:title>Full Text PDF</dc:title>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.frontiersin.org/articles/10.3389/fonc.2020.00221/pdf</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:46:49</dcterms:dateSubmitted>
        <z:linkMode>1</z:linkMode>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S0196978101005137">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:01969781"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Eto</foaf:surname>
                        <foaf:givenName>Tanenao</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:title>A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides</dc:title>
        <dc:date>11/2001</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S0196978101005137</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:55:26</dcterms:dateSubmitted>
        <bib:pages>1693-1711</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:01969781">
        <prism:volume>22</prism:volume>
        <dc:title>Peptides</dc:title>
        <dc:identifier>DOI 10.1016/S0196-9781(01)00513-7</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>Peptides</dcterms:alternative>
        <dc:identifier>ISSN 01969781</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S0196978111002154">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>32</prism:volume>
                <dc:title>Peptides</dc:title>
                <dc:identifier>DOI 10.1016/j.peptides.2011.05.022</dc:identifier>
                <prism:number>7</prism:number>
                <dcterms:alternative>Peptides</dcterms:alternative>
                <dc:identifier>ISSN 01969781</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kuwasako</foaf:surname>
                        <foaf:givenName>Kenji</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kitamura</foaf:surname>
                        <foaf:givenName>Kazuo</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nagata</foaf:surname>
                        <foaf:givenName>Sayaka</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hikosaka</foaf:surname>
                        <foaf:givenName>Tomomi</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Takei</foaf:surname>
                        <foaf:givenName>Yoshio</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kato</foaf:surname>
                        <foaf:givenName>Johji</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:title>Shared and separate functions of the RAMP-based adrenomedullin receptors</dc:title>
        <dc:date>07/2011</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S0196978111002154</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2022-03-05 16:55:41</dcterms:dateSubmitted>
        <bib:pages>1540-1550</bib:pages>
    </bib:Article>
    <z:Collection rdf:about="#collection_1">
        <dc:title>bev</dc:title>
        <dcterms:hasPart rdf:resource="https://doi.org/10.1093/biostatistics/kxw041"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682734/"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095028/"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228024/"/>
        <dcterms:hasPart rdf:resource="#item_21"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378489/"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682776/"/>
        <dcterms:hasPart rdf:resource="#item_29"/>
        <dcterms:hasPart rdf:resource="https://www.hindawi.com/journals/jo/2011/456743/"/>
        <dcterms:hasPart rdf:resource="https://doi.org/10.1186/s13058-015-0610-3"/>
        <dcterms:hasPart rdf:resource="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0070804"/>
        <dcterms:hasPart rdf:resource="https://clincancerres.aacrjournals.org/content/23/22/7059"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355275/"/>
        <dcterms:hasPart rdf:resource="#item_84"/>
        <dcterms:hasPart rdf:resource="https://www.sciencedirect.com/science/article/pii/S2405471215002185"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267726/"/>
        <dcterms:hasPart rdf:resource="https://www.nature.com/articles/s41467-020-19288-6"/>
        <dcterms:hasPart rdf:resource="#item_102"/>
        <dcterms:hasPart rdf:resource="http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-06-2072"/>
        <dcterms:hasPart rdf:resource="#item_106"/>
        <dcterms:hasPart rdf:resource="http://www.informatics.jax.org/vocab/gene_ontology/GO:0001525"/>
        <dcterms:hasPart rdf:resource="#item_111"/>
        <dcterms:hasPart rdf:resource="https://linkinghub.elsevier.com/retrieve/pii/S1043466612008198"/>
        <dcterms:hasPart rdf:resource="https://www.nature.com/articles/s41598-021-89754-8"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281832/"/>
        <dcterms:hasPart rdf:resource="#item_122"/>
        <dcterms:hasPart rdf:resource="#item_125"/>
        <dcterms:hasPart rdf:resource="#item_128"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922765/"/>
        <dcterms:hasPart rdf:resource="#item_838"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717957/"/>
        <dcterms:hasPart rdf:resource="https://www.nature.com/articles/s41598-021-85385-1"/>
        <dcterms:hasPart rdf:resource="https://www.frontiersin.org/article/10.3389/fonc.2020.00221"/>
        <dcterms:hasPart rdf:resource="https://linkinghub.elsevier.com/retrieve/pii/S0196978101005137"/>
        <dcterms:hasPart rdf:resource="https://linkinghub.elsevier.com/retrieve/pii/S0196978111002154"/>
    </z:Collection>
    <z:Collection rdf:about="#collection_9">
        <dc:title>ekg</dc:title>
        <dcterms:hasPart rdf:resource="#item_500"/>
        <dcterms:hasPart rdf:resource="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5331352/"/>
    </z:Collection>
    <z:Collection rdf:about="#collection_11">
        <dc:title>MN1</dc:title>
        <dcterms:hasPart rdf:resource="#item_666"/>
        <dcterms:hasPart rdf:resource="https://onlinelibrary.wiley.com/doi/abs/10.1111/neup.12514"/>
        <dcterms:hasPart rdf:resource="#item_669"/>
        <dcterms:hasPart rdf:resource="#item_670"/>
        <dcterms:hasPart rdf:resource="https://doi.org/10.1007/s10014-019-00346-x"/>
    </z:Collection>
    <z:Collection rdf:about="#collection_3">
        <dc:title>techniques</dc:title>
        <dcterms:hasPart rdf:resource="https://www.sciencedirect.com/science/article/pii/S0165027005004073"/>
        <dcterms:hasPart rdf:resource="#item_73"/>
        <dcterms:hasPart rdf:resource="#item_77"/>
        <dcterms:hasPart rdf:resource="#item_79"/>
        <dcterms:hasPart rdf:resource="https://www.nature.com/articles/nprot.2017.016"/>
    </z:Collection>
</rdf:RDF>
